



## 0900-1300 PAUSA Symposium

*Room: Ministres*

### 0900-0910 **Welcome and Introduction**

SIU President  
Joachim Thüroff, Germany

PAUSA President  
Serigne Gueye, Senegal

SIU 2010 Programme Chair  
Paul Abrams, UK

### Session I

Chairs: Fethi Meziane, Morocco  
Saeed Samnakay, Kenya

### 0910-0925 **Société Marocaine d'Urologie**

Abdennabi Joul, Morocco

### 0925-0940 **Nigerian Association of Urological Surgeons**

Alexander Nwofor, Nigeria

### 0940-0955 **Société Tunisienne d'Urologie: Use of Irrigation Fluid in Urology: Which Fluid and Why?**

Yassine Nouira, Tunisia

### 0955-1010 **Association Ivoirienne d'Urologie**

Georges Armand Ouegnin, Ivory Coast

### 1010-1025 **UroLink Lecture: Establishing and Maintaining an Overseas Link - Lessons To Be Learnt**

George Fowlis, UK

### 1025-1050 **Break**

### Session 2

Chair: Yassine Nouira, Tunisia

### 1050-1105 **Egyptian Association of Urology: The Problem of the Eneuretic Child**

Mohamed Eissa, Egypt

### 1105-1120 **Special Lecture**

Leslie Akporiaye, Nigeria

### 1120-1135 **Kenyan Association of Urological Surgeons**

Saeed Samnakay, Kenya

### 1135-1150 **African Gulf Society for Sexual Medicine: Surgical Management of Sexual Dysfunction**

Khaled Dabees, Egypt

### 1150-1205 **Association Française d'Urologie Prostate Cancer Screening—Which Policy in 2010?**

Pascal Rischmann, France

### 1205-1215 **Discussion**

### 1215-1300 **Panel: The Initiative for Urology Training in Africa**

Catherine deVries, USA  
Serigne Gueye, Senegal  
E. O. Olapade-Olaopa, Nigeria

### 1300-1400 **Lunch Break**



## 1400-1800 Association Marocaine d'Urologie Symposium

Room: Fès I

1400-1530

### Part 1: Urinary Diversion and Bladder Replacement

Chairs: Abdellatif Benchekroun, Morocco  
Abdennabi Joual, Morocco

#### Continent Urinary Diversion

1400-1420 Abdellatif Benchekroun

1420-1440 Fethi Meziane, Morocco

#### 1440-1500 Differential Indications for Continent vs. Incontinent Urinary Diversion

Detlef Frohneberg, Germany

1500-1520 **Bladder Replacement**

Abdennabi Joual

1520-1530 **Panel Discussion**

## 1530-1600 Break

1600-1700

### Part 2: Urinary Lithiasis

Chairs: Badreddine Kadiri, Morocco  
Mohamed Marzouk, Morocco  
Driss Touiti, Morocco

1600-1615 **Percutaneous Nephrolithotomy**

Mohamed Lezrek, Morocco

1615-1630 **Flexible Ureteroscopy**

Mohamed Tligui, Morocco

1630-1645 **Open Surgery**

Hamid Fekak, Morocco

1645-1700 **Laparoscopic Treatment**

Ismail Sarf, Morocco

1700-1800

### Part 3: Video Session

Chairs: Ahmed Alj, Morocco  
Redouane Rabii, Morocco

**V1 Percutaneous Treatment of Renal  
Hydatic Cyst**

Mohamed Lezrek, Morocco

**V2 Laparoscopic Ureteroneocystostomy and  
Vesicopsoas Hitch for the Management of  
Tuberculosis Lower Ureteric Stricture**

Fayçal Barjani, Morocco

**V3 Appendico-Ureteroplasty for Urethral  
Stricture**

S. El Yacoubi, Morocco

**V4 Renal Hydatic Cyst: Laparoscopic Surgery  
Tips and Tricks**

Redouane Rabii, Morocco

**V5 Laparoscopic Treatment of Cystocele**

Younès Haddane, Morocco

## 1400-1800 Urodynamics Course

Room: Karam 3

Chairs: Marcus Drake, UK  
Sherif Mourad, Egypt

### Voiding Diaries

### UDS for SUI and OAB

### UDS for Male Voiding Dysfunction

### UDS for Neurogenic Patients

### Interpretation of Results

### Writing a Report



1500-1800 **VVF Course**

*Room: Fès 2*

Chairs: Serigne Gueye, Senegal  
Mulu Muleta, Ethiopia

1500-1505 **Introduction**

Serigne Gueye

1505-1520 **Diagnosis and Evaluation**

Sanda Ganda, Niger

1520-1540 **Classification**

Kalilou Ouattara, Mali

1540-1610 **Management of Simple VVF**

Theobald Hategekimana, Rwanda

1610-1625 **Discussion**

1625-1655 **Management of Complex VVF**

Steve Arrowsmith, USA

1655-1725 **Management of SUI After  
Fistula Repair**

Mulu Muleta

1725-1740 **Discussion**

1740-1755 **Setting up a Facility for  
Fistula Treatment**

Serigne Gueye

1755-1800 **Conclusion**

Serigne Gueye

1800-1900 **Opening Ceremonies**

*Room: Ministres*

1900-2000 **Exhibit Hall Opening and  
Welcome Reception**

*Room: Royale*



MARRAKECH 2010



## 0700-0815 Sponsored Symposium

*Room: Fès I*

*Breakfast will be served from 0630.*

### Cook Medical

#### Biodesign Surgisis for Peyronie's Repair: When Does Surgisis Work, When Does it Fail and Why?

Chair: Kenneth W. Angermeier, USA

#### 0700-0710 Introduction

Kenneth W. Angermeier

#### 0710-0730 Surgisis Biodesign - My Failed Patients

Richard A. Santucci, USA

#### 0730-0750 Surgisis Biodesign - My Successful Patients

Gerald H. Jordan, USA

#### 0750-0810 Panel Discussion and Q&A

All

#### 0810-0815 Closing Comments

Kenneth W. Angermeier

## 0700-0800 Surgical Tips: VVF

*Room: Ambassadeurs*

Chairs: Serigne Gueye, Senegal  
Suzy Elneil, UK

#### 0700-0715 How I Do Transvaginal VVF Repair

Kalilou Ouattara, Mali

#### 0715-0730 How I Do Transabdominal VVF Repair

Issa Labou, Senegal

#### 0730-0745 How I Manage Circumferential VVF

Steve Arrowsmith, USA

#### 0745-0800 Discussion

## 0815-1015 Plenary: The Overactive Bladder

*Room: Ministres*

Chair: Marcus Drake, UK

#### 0815-0820 Introduction

Marcus Drake

#### 0820-0845 Pathophysiology of OAB

Marcus Drake

#### 0845-0910 Assessment of OAB/DO

Sender Herschorn, Canada

#### 0910-0935 Evidence-based Medical Treatment of OAB

Luc Valiquette, Canada

#### 0935-1000 Treating OAB Drug Failure

J.L.H Ruud Bosch, Netherlands

#### 1000-1015 Discussion

## 1015-1030 Break Unmoderated Posters

*Room: Royale*

## 1030-1230 Plenary: Report of the 1st ICUD-SIU Consultation on VVF

*Room: Ministres*

Chairs: Zakaria Behlanch, Morocco  
Serigne Gueye, Senegal

#### 1030-1050 Epidemiology

Mulu Muleta, Ethiopia

#### 1050-1110 Prevention Strategies

Alice Emasu, Uganda

#### 1110-1130 Unmet Needs

Suzy Elneil, UK



1130-1150 **Surgery for Fistula**

Dirk De Ridder, Belgium

1150-1210 **Complications from Fistula**

Sherif Mourad, Egypt

1210-1230 **Social Integration**

Rahmat Mohammad, Nigeria

1230-1345 **Lunch Break**

1230-1345 **Sponsored Symposium**

*Room: Ambassadeurs*

### **Astellas Pharma**

#### **OAB: The Grand Round**

Chair: Paul Abrams, UK

1230-1235 **Introduction**

Paul Abrams

1235-1255 **Patient Communication**

Gamal Ghoniem, USA

1255-1315 **Managing the Female Patient**

Chris Payne, USA

1315-1335 **Managing the Male Patient**

Jose Emilio Batista, Spain

1335-1345 **Question and Answer Session**

Paul Abrams

1345 **Summary and Close**

1345-1545 **Plenary: Post-Prostatectomy Incontinence**

*Room: Ministres*

Chairs: Ahmed Ameer, Morocco  
Anthony Schaeffer, USA

1345-1405 **AUA Lecture: Incontinence—Past, Present, Future**

Anthony Schaeffer

1405-1425 **Technical and Anatomical Features in the Avoidance of Post-Radical Prostatectomy Urinary Incontinence**

Vincent Delmas, France

1425-1445 **Postoperative Rehabilitation for Continence**

Christian Hampel, Germany

1445-1505 **Mechanics of Incontinence and Diagnostics**

Dirk De Ridder, Belgium

1505-1545 **Case Presentations and Discussion**

Faculty

1545-1600 **Break Unmoderated Posters**

*Room: Royale*



## 1600-1800 Plenary: Infections

*Room: Ministres*

Chairs: Chris F. Heyns, South Africa  
Mouâd Nouri, Morocco

### 1600-1605 **Introduction**

Chris F. Heyns

### 1605-1625 **Tuberculosis**

Redouane Rabii, Morocco

### 1625-1645 **Bilharzia**

Kasonde Bowa, Zambia

### 1645-1705 **The Role of Circumcision on HIV Prevention**

Stephen Watya, Uganda

### 1705-1725 **Global Alliance for Elimination of Lymphatic Filariasis**

Sunny Doodu Mante, Ghana

### 1725-1745 **Surgery of Lower Urinary Tract Bilharzial Complications**

Ismail Khalaf, Egypt

### 1745-1800 **Discussion**

## 1600-1730 Podium Session 1: Post-Prostatectomy Incontinence

*Room: Fès I*

Chairs: Jerzy Gajewski, Canada  
Homero Bruschini, Brazil

1600-1610

### **POD-I.01**

### **The Effect of Nerve-Sparing Status in the Recovery of Continence After Radical Prostatectomy**

Yunbyung Chae, South Korea

1610-1620

### **POD-I.02**

### **Treatment of Refractory Postoperative Urinary Stress Incontinence by the Use of Autologous Satellite Cells (SLC)**

Roman Karig, Germany

1620-1630

### **POD-I.03**

### **Mid-term Results of the Functional Transobturator Sling Suspension for Male Post-Prostatectomy Stress Urinary Incontinence**

Ricarda M. Bauer, Germany

1630-1640

### **POD-I.04**

### **The Bone-Anchored Perineal Male Sling for Post-Prostatectomy Incontinence: Results Up to 5 Years of Follow-Up**

Miguel Guimaraes, Portugal



1640-1650

**POD-I.05**

### Long Term Results after AdVance Male Sling Procedure in Male Stress Urinary Incontinence (SUI)

Axel Hegele, Germany

1650-1700

**POD-I.06**

### Male Slings: A Comparative Study of Two Techniques

Gamal Ghoniem, USA

1700-1710

**POD-I.07**

### Treatment of Stress Urinary Incontinence Due to Neurogenic Sphincter Insufficiency Using the AdVance Male Sling

Reynaldo Gómez, Chile

1710-1720

**POD-I.08**

### The Artificial Urinary Sphincter: A Contemporary Series

Priyadarshi Kumar, UK

1720-1730

**POD-I.09**

### AdVance Sling: The 'Repositioning Test', the Most Important Tool for Preoperative Evaluation

Ricarda M. Bauer, Germany

## 1600-1800 Moderated Poster Sessions 1-3

### MODERATED POSTER SESSION I

#### MALE LOWER URINARY TRACT SYMPTOMS

*Room: Karam 1*

Chairs: Emmanuel Chartier-Kastler, France  
Mark Speakman, UK

**MP-01.01**

### The Effect of Anticholinergics to Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms and the Risk Factors to Affect Patient's Satisfaction

Tae Hyo Kim, South Korea

**MP-01.02**

### Diagnostic Performance of Simple Tests Used by General Practitioners in Identifying Benign Prostatic Hyperplasia (BPH): Results from the D-IMPACT (Diagnosis Improvement in Primary Care Trial)

Richard Olivier Fourcade, France

**MP-01.03**

### Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, and Metabolic Syndrome

Catalin Pricop, Romania

**MP-01.04**

### Prospective Comparison of a New Visual Prostate Symptom Score versus the International Prostate Symptom Score in Men with Lower Urinary Tract Symptoms

Chris Van Der Walt, South Africa

**MP-01.05**

### Sexual Dysfunction in Patients with LUTS due to Benign Prostatic Enlargement

Mohamed Ali, Egypt



**MP-01.06** Impact of Erectile Function in Men with Lower Urinary Tract Symptoms on Ejaculatory Function

Sung Chul Kam, South Korea

**MP-01.07** LUTS and Semen Quality of Korean Men in Their 4th Decade

Seung-Hun Song, South Korea

**MP-01.08** Does the Effect of Alpha-Blockers in a Patient with a Small Prostate Differ Urodynamically from One with a Large Prostate?

Hirofumi Iuchi, Japan

**MP-01.09** Tailoring Pharmacotherapy of Male Lower Urinary Tract Symptoms with  $\alpha$ -Blockers,  $\alpha$ -Reductase Inhibitors, and Antimuscarinics

Kyu-Sung Lee, South Korea

**MP-01.10** Efficacy of Tamsulosin OCAS™ plus Solifenacin (TOCAS+Soli) in Male LUTS: Results From a Randomized, Dose-ranging, Phase II Trial (SATURN)

Philip Van Kerrebroeck, Netherlands

**MP-01.11** Outpatient Work-Up for LUTS: An Assignment for Specially Trained Nurses (STNs)?

Peter Ströberg, Sweden

**MP-01.12** Outcomes of Patients Treated Medically for Benign Prostatic Hyperplasia (BPH) in French General Practice

Richard Olivier Fourcade, France

**MP-01.13** Actual Medical Management of LUTS/BPH Across Europe Beyond Official Clinical Guidelines: A Wide Population Study

Jean-Nicolas Cornu, France

**MP-01.14** Benign Prostatic Hyperplasia: Where Evidence-Based Medicine Should Face Reality

Jean-Nicolas Cornu, France

**MODERATED POSTER SESSION 2  
STRICTURES/VVF**

*Room: Karam 2*

Chairs: Dirk De Ridder, Belgium  
Gerald Jordan, USA

**MP-02.01** Management of Adult Anterior Urethral Stricture Disease: Nationwide Survey among Urologists in the Netherlands

Menno Alexander Van Leeuwen  
Netherlands

**MP-02.02** Predictors of Recurrence in Optical Urethrotomy (OU) for Male Urethral Strictures

Ali Akbar Zehri, Pakistan

**MP-02.03** Results of Dorsal Buccal Graft Augmented Anastomosis for Urethral Strictures

Britton E. Tisdale, USA



**MP-02.04** Versatility of Ventral Onlaid Buccal Mucosal Graft Urethroplasty in Treatment of Penile and Meatal Strictures in Conjunction with the Dartos Fascial Flap

James Wong, Australia

**MP-02.05** Urinary Function and QOL in Men >60 Undergoing Perineal Urethrostomy vs. Urethral Reconstruction

Hadley Wood, USA

**MP-02.06** Erectile Function after End-To-End Repair, Buccal Mucosa Roof Strip Augmented Anastomosis or Dorsal-Inlay Buccal Mucosa Graft Urethroplasty for Single-Stage Bulbar Urethroplasty

Kathy Vander Eeckt, Belgium

**MP-02.07** Wound Complications After Urethral Reconstruction and the Effect of a Monocryl Mattress Closure on Healing

Keith Rourke, Canada

**MP-02.08** Long-Term Outcomes of Urethral Reconstruction: Risk Factors for Stricture Recurrence

Keith Rourke, Canada

**MP-02.09** The Treatment of Urethral Stricture Disease at the Department of Urology, University of The Free State, South Africa: Patient Profile, Management and Outcome

Frederik Claassen, South Africa

**MP-02.10** Vesico-Vaginal Fistula Repair: Unique Experience in Young Multigravida, Multicaesarian Patients from Jazan Region, Saudi Arabia

Akhileshwar Jha, Kingdom of Saudi Arabia

**MP-02.11** Application of Small Intestinal Submucosa Graft in Repair of Complicated Vesico-Vaginal Fistula: Pilot Study

Yasser Farahat, Egypt

**MP-02.12** A Versatile Labia Minora Skin Flap in Severe Vesico-Vaginal Fistula Repair

Marta Bizic, Serbia

**MP-02.13** Laparoscopic Vesico-Vaginal Fistula Repair: 9 Cases

Reynaldo Gómez, Chile

**MP-02.14** The Effect of Intra-Corpus Spongiosum Mitomycin-C Injection Therapy Combined with Optic Internal Urethrotomy in the Treatment of Anterior Urethral Strictures: Does It Improve the Treatment Outcome?

Frederik Claassen, South Africa



**MP-02.15** Adult Urethral Strictures in Previous Hypospadias Patients

Vladimir Kojovic, Serbia

**MP-02.16** Preliminary Results of Mitomycin on Recurrent Bladder Neck Contracture after Radical Prostatectomy

Le Mai Tu, Canada

**MP-02.17** Bladder Outlet Obstruction (BOO) Post BPH Surgery: Over 3 Years' Follow-Up Using Holmium Laser: Our Department Experience

Francesco Pisanti, Italy

**MODERATED POSTER SESSION 3  
BASIC SCIENCE/CHRONIC PELVIC  
PAIN SYNDROME**

Room: Karam 3

Chairs: J. Curtis Nickel, Canada  
Anthony Schaeffer, USA

**MP-03.01** In Vitro Test System for the Evaluation of the Biocompatibility of Alloplastic Materials and Its Improvement by Autologous Coating

Jens-Willem Bagner, Germany

**MP-03.02** The Expression of Transient Receptor Potential Channels in the Urothelium of Rats with Detrusor Overactivity Induced by Bladder Outlet Obstruction

Chong Koo Sul, South Korea

**MP-03.03** Bladder Outlet Obstruction Modulates Ca<sup>2+</sup> Sensitization in Alpha-Toxin Permeabilized Guinea-pig Detrusor Smooth Muscle

Shunichi Kajioaka, Japan

**MP-03.04** The Effect of Continuous PDE-5 Inhibitors in CPPS

Dae-Yeon Cho, South Korea

**MP-03.05** The Collagen Composition of the Bladder Wall Extracellular Matrix Is Influenced by Hypercholesterolemic Diet in Rats

Homero Bruschini, Brazil

**MP-03.06** A Fluid Dynamic Model Matched for Voiding Dysfunction in Bladder Outlet Obstruction

Gaku Sakuyama, Japan



**MP-03.07** Does Finasteride Have a Preventive Effect on a Chronic Bacterial Prostatitis? Pilot Study Using an Animal Model

Yong-Hyun Cho, South Korea

**MP-03.08** Significance of Histological Evidence of Prostatitis in Men with Urinary Retention and Underlying Benign Prostatic Hyperplasia or Adenocarcinoma of the Prostate

Amir Zarrabi, South Africa

**MP-03.09** The Levels of Serum C-reactive Protein and Urinary Nerve Growth Factor in Patients with OAB and IC/BPS

Yi-Shiou Tseng, Taiwan

**MP-03.10** Urinary Nerve Growth Factor in OAB and Cystitis

Ju Tae Seo, South Korea

**MP-03.11** Improvement of Pain and Sleep Problems by Urine Alkalinization in Patients with Interstitial Cystitis

Kim Drasa, Albania

**MP-03.12** The Effect of Tamsulosin 0.2mg in Patients with Chronic Pelvic Pain Syndrome: Multicenter, Randomized, Prospective Study

Tae Hyo Kim, South Korea

**MP-03.13** Hyperbaric Oxygen (HBO) Therapy Suppresses the Symptoms in Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC) Resistant to Conventional Treatments: Long Term Result of a Pilot Study in Japan

Tomoaki Tanaka, Japan

**MP-03.14** One-year Follow-up of Extracorporeal Shock Wave Therapy (ESWT) for Chronic Pelvic Pain Syndrome (CPPS) in a Randomized Placebo-Controlled Double Blind Study

Reinhold Zimmermann, Austria

**MP-03.15** Ketamine Abuse: New Causative Factor of LUTS

Seshikanth Middela, United Kingdom

**MP-03.16** The Role of the Effect of Cav3.2/  $\alpha$ 1H T-type Calcium Channel on Voiding

Dong Ki Lee, South Korea



## 1600-1730 Moderated Video Session 1 Various Topics

*Room: Karam 5*

Chairs: Zakaria Belahnech, Morocco  
Antonio Carlos Pompeo, Brazil

1600-1610

**VID-1.01**

**Combined Endoscopic and Surgical Treatment for Bladder Erosion by Prolene Mesh**

Alessandra Ambu, Italy

1610-1620

**VID-1.02**

**Simultaneous Correction of Anterior, Apical Prolapse and Stress Urinary Incontinence with the Anterior Prolift System**

Ivan Ignjatovic, Serbia

1620-1630

**VID-1.03**

**LESS Transvesical VVF Repair**

Pradeep Rao, India

1630-1640

**VID-1.04**

**Genitourinary Reconstruction of Urogenital Sinus Variant**

Bassem Wadie, Egypt

1640-1650

**VID-1.05**

**One-stage Reconstruction of the Urethra and Bladder Neck, Following Severe Obstetric Trauma**

Bassem Wadie, Egypt

1650-1700

**VID-1.06**

**Management of Rectourinary Fistula: The York Mason Approach**

Vincent Flamand, France

1700-1710

**VID-1.07**

**Pelvic Lipomatosis Causing Lower Urinary Tract Symptoms and Renal Failure: Surgical Management with Bilateral Ureteric Reimplantation**

Shaun Smit, South Africa

## 0900-1600 Unmoderated Poster Session 1

*Room: Royale*

**UP-1.01**

**Impact of Lower Urinary Tract Symptoms on Sexual Function in Patients with Symptomatic Prostatic Disorders**

Mohamed Ali, Egypt

**UP-1.02**

**Urinary Incontinence in Patients with Symptomatic Benign Prostatic Enlargement: Features and Impact on Sexual Dysfunction**

Mohamed Ali, Egypt

**UP-1.03**

**Lower Urinary Tract Symptoms and Sexual Dysfunction in Women: Correlation of Symptoms with Urodynamic Parameters**

Kaan Bal, Turkey



**UP-1.04** Interest of Uroflowmetry in Prostatic Hyperplasia

Nordine Benhatchi, Algeria

**UP-1.05** Clinical Significance of Detrusor After Contraction

Seung June Oh, South Korea

**UP-1.06** Urinary Diversion Continence: Pocket Casablanca

Mohamed Anis Khelil, Morocco

**UP-1.07** Bladder Pheochromocytoma Conservative Treatment: Endoscopic Surgery Coupled with Open Surgery

Mohamed Anis Khelil, Morocco

**UP-1.08** Lower Urinary Tract Symptoms in Patients with Familial Amyloidotic Polyneuropathy

Rui Farinha, Portugal

**UP-1.09** Impact of Benign Prostatic Hyperplasia (BPH) on Medically Treated Patients' Quality of Life

Richard Olivier Fourcade, France

**UP-1.10** Urinary Incontinence in Obese People: Urodynamics Studies

Barbara Cristina Gentile, Italy

**UP-1.11** Is TURP Possible Without Postoperative Irrigation?

Omar Ghoundale, Morocco

**UP-1.12** Anastomotic Stricture after Radical Prostatectomy: Risk Factors

Tomas Hanus, Czech Republic

**UP-1.13** The Efficacy and Safety of Combined Therapy with Tamsulosin and Tolterodine for Female Patients with a Maximal Flow Rate Less than 12ml/sec

Soo Bang Ryu, South Korea

**UP-1.14** The Effect of Chronic Prostatic Inflammation and Prostatic Calculi on Benign Prostatic Hyperplasia

Hyun Woo Kim, South Korea

**UP-1.15** The Effect of Intraprostatic Chronic Inflammation on Benign Prostate Hyperplasia Treatment

Choal Hee Park, South Korea

**UP-1.16** Long-Term Effect of Loxoprofen Sodium on Nocturia in Patients with Benign Prostatic Hyperplasia

Choal Hee Park, South Korea

**UP-1.17** Is There a Best Method for Measurement of Q Tip Angle?

Chang-Ho Lee, South Korea

**UP-1.18** Sacral Neuromodulation: Utility if Reprogramming During the Initial Test Phase

Johann Ménard, France



- UP-I.19** The Role of Urodynamics in the Management of Children's Vesicoureteric Reflux  
Mártha Orsolya, Romania
- UP-I.20** Effect of Increasing the Dose of Tamsulosin to 0.4 Mg on Dysuria Associated with Benign Prostatic Hyperplasia  
Takehiko Okamura, Japan
- UP-I.21** Large Prostate Volume is a Risk Factor of Pyuria in Patients with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms  
Seung Chol Park, South Korea
- UP-I.22** Differential Diagnosis of Lower Urinary Tract Symptoms in Elderly Men: A 7-Year Retrospective Analysis of Symptoms and Urodynamics  
Jaeshin Park, South Korea
- UP-I.23** Evaluation of Lower Urinary Tract Symptoms in Men with Type II Decompression Sickness  
Emmanuel Patris, Greece
- UP-I.24** The Relationship Between Clinical Outcome of Photoselective Vaporization Prostatectomy and Pressure Flow Study  
Youngjun Seo, South Korea
- UP-I.25** The Urodynamic Alterations of Patients with Varying Degrees of Cystocele  
Dong Gil Shin, South Korea
- UP-I.26** The Role of Alpha 1(A) Adrenoceptor Antagonist Tamsulosin for the Treatment of Patients with Lower Urinary Tract Symptoms in Women: The Effect of Nocturia and Sleep Quality  
Soo Bang Ryu, South Korea
- UP-I.27** TRUS Assisted Transurethral Incision of Ejaculatory Ducts (TUIED): A Novel Technique  
Muthu Veeramoni, India
- UP-I.28** Additive Tolterodine for Elderly Male LUTS in Taiwan  
Wei-Che Wu, Taiwan
- UP-I.29** Greenlight HPS Laser Photoselective Vaporisation Prostatectomy in a District General Hospital  
Hussain Alhajjar, UK
- UP-I.30** Comparison of Clinical Outcome between Benign Prostatic Hyperplasia Patients With and Without Extension of the Prostate into Urinary Bladder After Transurethral Resection of the Prostate  
Shiou-Sheng Chen, Taiwan



**UP-I.31** Factors That Contribute to Improve Qmax After Transurethral Resection of the Prostate

In-Rae Cho, South Korea

**UP-I.32** Predictors of Successful Cessation of Alpha-blockers in Patients with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms: A Pilot Study

Kang Su Cho, South Korea

**UP-I.33** Could Elevated Prostate-Specific Antigen Be a Useful Marker for Bladder Outlet Obstruction?

Seong Choi, South Korea

**UP-I.34** Changes in Lower Urinary Tract Symptoms After Cryosurgical Ablation for Prostate Cancer

Seong Choi, South Korea

**UP-I.35** An Analysis of the Factors of Bladder Irritation Symptoms After Transurethral Resection of the Prostate (TURP)

Jae-Hung Jung, South Korea

**UP-I.36** Definitive Assessment of Early Post-Operative Symptoms After Laser Photovaporization of the Prostate (PVP): Validation of a Dedicated Questionnaire

Jean-Nicolas Cornu, France

**UP-I.37** Prospective Evaluation of Transurethral Needle Ablation (TUNA) Procedure in an Ambulatory Setting

Jean-Nicolas Cornu, France

**UP-I.38** Short-Term Results on Efficacy and Safety of High Power (80W) KTP (Potassium-Titanyl-Phosphate) Laser Vaporization of the Prostate

Young-Joo Kim, South Korea

**UP-I.39** Long Intraprostatic Urethral Length as a Cause of Lower Urinary Tract Symptoms in Patients with Prostate Volume Less than 25 cm<sup>3</sup>

Seung Ryeol Lee, South Korea

**UP-I.40** Short-Term Results of Bladder Hydrodistention for Interstitial Cystitis in Young Adult Men

Seung Ki Min, South Korea

**UP-I.41** The Role of Trial Without Catheter in the Initial Management of Acute Urinary Retention Due to Benign Prostatic Hyperplasia

Oana Pojoga, Romania

**UP-I.42** The Prevalence of Benign Prostate Hyperplasia in a Rural Community of South Korea

Hong Yong Choi, South Korea

**UP-I.43** Penetration Depth is Key: The Optimal Treatment of BPH (Benign Prostatic Hyperplasia) Using Multi-disciplinary Laser DIOLAS LFD 3000 for Photoselective Vaporization of the Prostate

Joerg Neymeyer, Germany



UP-I.44

Laser Vaporization for the Treatment of BPH: Prospective Study with an Eighteen-Month Follow-Up

Richard Olivier Fourcade, France

UP-I.45

Efficacy of TURP for the Treatment of BPH in Patients with Diabetes Mellitus

Georgios Papadopoulos, Greece

UP-I.46

The Results of Retropubic Prostatectomy and Transurethral Resection of Prostate: Compare Both Results, and then Investigate the Cause of Different Results

Sung-Woo Park, South Korea

UP-I.47

A Novel Technique Combining Bipolar and LESS Enucleation for BPH

Pradeep Rao, India

UP-I.48

Management of Acute Urinary Retention Associated with Benign Prostatic Hyperplasia in Real Life Practice in Thailand

Krisada Ratana-Olam, Thailand

UP-I.49

Management of Chronic Retention: Overcoming a Dilemma

Ravindra Sabnis, India

UP-I.50

Tadalafil Monotherapy Is as Efficacious as Tamsulosin in Patients with LUTS Secondary to BPH: Results of First Head-on Comparative, Prospective, Randomized Study to Evaluate the Efficacy of Tadalafil and Tamsulosin, in Patients with LUTS Secondary to BPH

Ravindra Sabnis, India

UP-I.51

Tolterodine and Tamsulosin for Treatment of Men with Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms

Vasile Dan Stanca, Romania

UP-I.52

Lower Urinary Tract Symptoms in Men with Prostate Cancer: Correlation with Cancer Control

Chris Van der Walt, South Africa

UP-I.53

The Introduction of a Prostate Holmium Laser Service to a District General Hospital (DGH)

Lona Vyas, UK

UP-I.54

The Alteration of Autonomic Nervous System Activity in Women with Urge Urinary Incontinence

Jong Bo Choi, South Korea

UP-I.56

Effectiveness of Botulinum Toxin Type A in the Management of Neurogenic Lower Urinary Tract Dysfunction

Reynaldo Gómez, Chile



**UP-I.57** Effect of Clean Intermittent Catheterization on PSA Levels of Spinal Cord Injured Patients

Marcos Lucon, Brazil

**UP-I.58** Efficacy of Clean Intermittent Catheterization (CIC) for Urinary Incontinence in Children with Neurogenic Bladder Dysfunction Secondary to Myelodysplasia

Kenji Obara, Japan

**UP-I.59** Urological Features of Quadriplegia: Six Years of Experience

Cristian Persu, Romania

**UP-I.60** Preliminary Report of the First Experience of Sacral Neuromodulation in Iranian Patients with Voiding Dysfunction

Farzaneh Sharifiaghdas, Iran

**UP-I.61** Prostatic Inflammation and Prostate Cancer: Is There Evidence for a Link?

Paul F. Engelhardt, Austria

**UP-I.62** Pelvic Drain Can Be Avoided After Transvesical Prostatectomy for Prostate Benign Hyperplasia

Omar Ghoundale, Morocco

**UP-I.63** Use of Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Secondary to Pelvic Radiotherapy

Reynaldo Gómez, Chile

**UP-I.64** Impact of Dutasteride on Serum Testosterone and Body Mass Index in Men with Benign Prostatic Hyperplasia

Sung Kyu Hong, South Korea

**UP-I.65** Effect of Silodosin on Ejaculation Function and QOL in Patients with Lower Urinary Tract Syndrome (LUTS)

Teruaki Iwamoto, Japan

**UP-I.66** The Correlation Between Serum Parathyroid Hormone and Prostate Size in Patients with Benign Prostatic Hyperplasia

Won Tae Kim, South Korea

**UP-I.67** Diagnostic Value of Functional Bladder Capacity, Urine Osmolality and Daytime Storage Symptoms for Severity of Nocturnal Enuresis

Jun-Mo Kim, South Korea

**UP-I.68** Results of Patients' Questionnaires after Photoselective Vaporisation of the Prostate: Single Institution Survey

Jiri Klecka, Czech Republic

**UP-I.69** Cystocele Plication Risk (CPR) Trial: A Pilot Study

Victor Miranda, Canada

**UP-I.70** Impact of Preoperative Urinary Dysfunction on Functional Outcomes Following Open Radical Prostatectomy

Shinya Yamamoto, Japan



**UP-1.71** Urinary Continence after Open, Laparoscopic and Robotic Prostatectomy: A Single Center Experience

Youssef El Aidi, Romania

**UP-1.72** Antegrade Approach Provides Higher and Earlier Continence Rates and Better Health-Related Quality of Life on Urination Following Radical Prostatectomy

Akiko Fujisaki, Japan

**UP-1.73** Primary Results of Argus Readjustable Male Sling After 15 Cases

Thomas Arvanitakis, Greece

**UP-1.74** Evaluation and Classification of Sphincter Lesions Due to Radical Prostatectomy (RP)

Roman Karig, Germany

**UP-1.75** Results of Simultaneous Implantation of Inflatable Penile Prosthesis and Bone-Anchored Bulbourethral Sling After Radical Prostatectomy

Rui Oliveira, Portugal

**UP-1.76** Capio RP Suturing Device for Vesico-Urethral Anastomosis Improves Urinary Continence and Postsurgical Strictures Rates After Radical Retropubic Prostatectomy

Giacomo Perugia, Italy

**UP-1.77** Postoperative Status of Bladder Outflow and Early Catheter Removal After Radical Retropubic Prostatectomy

Giacomo Perugia, Italy

**UP-1.78** The Adjustable Transobturator Tape (TOT) for Post-Prostatectomy Incontinence

Fatih Yalcinkaya, Turkey

**UP-1.79** The Association Between Lower Urinary Tract Symptoms and Vascular Risk Factors in Aging Men: Hallym Aging Study

Seong Ho Lee, South Korea

**UP-1.80** Robotic-Assisted Laparoscopic Radical Cystectomy (RARC) with Extracorporeal Urinary Diversion and Robotic-Assisted Laparoscopic Partial Cystectomy (RAPC)

Seil Jung, South Korea



MARRAKECH 2010



## 0700-0815 Sponsored Symposium

*Room: Ambassadeurs*

*Breakfast will be served from 0630.*

### Astellas Pharma

#### Unravelling the Colour Spectrum of Male LUTS

Chair: Mark Speakman, UK

#### 0700-0710 Introduction

Mark Speakman

#### 0710-0720 Male LUTS: Need for Better Assessment of Storage Symptoms

Tim Schneider, Germany

#### 0720-0745 Improving Nocturia and Sleep: Colouring Your Patient's Day

Emmanuel Chartier-Kastler, France

#### 0745-0810 Male LUTS: Which Direction In Case of Persistent Storage Symptoms

David Castro-Díaz, Spain

#### 0810-0815 Closing Remarks

Mark Speakman

## 0700-0800 Surgical Tips: Post-Prostatectomy Incontinence

*Room: Fès I*

Chair: Dirk De Ridder, Belgium

#### 0700-0705 Welcome and Introduction

Dirk De Ridder

#### 0705-0720 Artificial Spincter

Sender Herschorn, Canada

#### 0720-0735 InVance Male Sling

Ajay Singla, USA

#### 0735-0750 AdVance Sling

Dirk De Ridder

#### 0750-0800 Discussion

All

## 0815-1015 Plenary: Male Voiding Dysfunction

*Room: Ministres*

Chairs: Ismail Sarf, Morocco  
Joachim Thüroff, Germany

#### 0815-0835 EAU Lecture: MLUTS Assessment and Triage

Christopher Chapple, UK

#### 0835-0840 Discussion

#### 0840-0900 Medical Therapy for BPO International Perspective

Mark Speakman, UK

#### 0900-0905 Discussion

#### 0905-0950 MIS—An Advance, Cost-Effective?

Christopher Cheng, Singapore  
Andreas Gross, Germany  
Rainer Kuntz, Germany

#### 0950-1015 Panel Discussion

## 1015-1030 Break Unmoderated Posters

*Room: Royale*



1030-1230 **Plenary: Urological Chronic Pelvic Pain Syndromes (UCPPS): 2000-2010, A Decade of Progress**

*Room: Ministres*

Chair: J. Curtis Nickel, Canada

1030-1035 **Introduction**

J. Curtis Nickel

1035-1050 **The Evolution of Definitions, Diagnosis and Nomenclature**

Jean-Jacques Wyndaele, Belgium

1050-1105 **Evidence-based Management of Male UCPPS (Chronic Prostatitis/Chronic Pelvic Pain Syndrome)**

Michel Pontari, USA

1105-1120 **Evidence-based Management of Female UCPPS (Interstitial Cystitis/Bladder Pain Syndrome)**

Jorgen Nordling, Denmark

1120-1150 **Debate: Are Male and Female UCPPS the Same Condition?**

1120-1130 **Pro**

Karl Kreder, USA

1130-1140 **Con**

Anthony Schaeffer, USA

1140-1150 **Debate**

1150-1205 **Case-based Debate: When Evidence-based Medicine Fails, What Next?**

Faculty

1205-1220 **What Have We Learned/Where Are We Going?**

J. Curtis Nickel

1220-1230 **Discussion**

1230-1345 **Lunch Break**

1230-1330 **Sponsored Symposium**

*Room: Fès 1*

**GlaxoSmithKline**

**Effective Management of BPH with Combination Therapy**

Chair: Abdennabi Joual, Morocco

1230-1235 **Introduction**

Abdennabi Joual

1235-1315 **Effective Management of BPH with Combination Therapy**

Claus Roehrborn, USA

1315-1325 **Question and Answer Session**

Claus Roehrborn, USA

1325-1330 **Summary and Closing Remarks**

Abdennabi Joual

1230-1345 **Sponsored Symposium**

*Room: Fès 2*

**Pfizer**

**Toviaz®: Opening the Door to Individualized Care**

1230-1235 **Welcome and Introduction**

1235-1250 **Building on The Detrusitol Legacy**

1250-1310 **Opening the Door to Toviaz®**

1310-1330 **Toviaz® 4 mg and 8 mg for Individualized Care**

1330-1345 **Panel Discussion and Q&A**



1345-1545 **Plenary: ICUD Consultation on Urethral Strictures: Committee Presentations**

*Room: Ministres*

Chairs: Gerald H. Jordan, USA  
Christopher Chapple, UK  
Chris F. Heyns, South Africa

1345-1357 **Epidemiology, Anatomy and Nomenclature**

Jerilyn Latini, USA

1357-1409 **Evaluation and Follow-up**

Ken Angermeier, USA

1409-1421 **IU/Dilations/Stents**

Jill Buckley, USA

1421-1433 **Anterior Urethra-Primary Anastomosis**

Nick Watkin, UK

1433-1445 **Anterior Urethra-Lichen Sclerosis**

Kurt McCammon, USA

1445-1457 **Anterior Urethra-Single Stage Substitution**

Christopher Chapple, UK

1457-1509 **PFUDD**

Reynaldo Gómez, Chile

1509-1521 **Vesico-Urethral Stenosis after Treatment for Prostate Cancer**

Sender Herschorn, Canada

1521-1533 **Pediatric Strictures**

George Kaplan, USA

1533-1545 **Discussion**

1545-1600 **Break  
Unmoderated Posters**

*Room: Royale*

1600-1800 **Podium Session 2  
Neuro-Urology**

*Room: Fès I*

Chairs: David Castro-Díaz, Spain  
Hassan Shaker, Egypt

1600-1610

**POD-2.01**

**Retropubic Bulbourethral Sling in Children with Post-Exstrophy Incontinence: Preliminary Report**

Bassem Wadie, Egypt

1610-1620

**POD-2.02**

**Outcome of Dual Flange Metallic Sphincteric Urethral Stents in the Treatment of Neuropathic Bladder Dysfunction After Spinal Cord Injury**

Chris F. Heyns, South Africa

1620-1630

**POD-2.03**

**Can We Predict Complications from Known Classifications of Neurogenic Voiding Dysfunction?**

Sung-Jin Kim, South Korea

1630-1640

**POD-2.04**

**Neurogenic Detrusor Overactivity in Adults: A Review of the Efficacy of Oral Antimuscarinics**

Helmut Madersbacher, Austria

1640-1650

**POD-2.05**

**Reality of Urinary Incontinence in Patients with Parkinson's Disease**

Young-Joo Kim, South Korea



1650-1700

**POD-2.06**

Effect of T-Type Calcium Channel Blocker Mibefradil on Cyclophosphamide-Induced Cystitis in Mouse

Hyun Wook You, South Korea

1700-1710

**POD-2.07**

Laparoscopic Augmentation Ileocystoplasty: Urodynamic Findings and Long-Term Outcome

Mahmoud Abdel Hakim, Egypt

1710-1720

**POD-2.08**

Bladder Augmentation for Hyperactive Spinal Cord Neurogenic Bladder: Comparison of Open Versus Laparoscopic Ileocystoplasty

Reynaldo Gómez, Chile

1720-1730

**POD-2.09**

Real-Time MRI for Visualization of Differences in Continent and Incontinent Patients with Neobladder

Ricarda M. Bauer, Germany

1730-1740

**POD-2.10**

Surgery of the Spinal Cord Injury Neurogenic Bladder: A 23 Year Experience

Reynaldo Gómez, Santiago, Chile

1600-1800 **Moderated Poster Sessions 4-6**

#### **MODERATED POSTER SESSION 4 STRESS URINARY INCONTINENCE**

*Room: Karam I*

Chairs: Gamal Ghoniem, USA  
Karl Kreder, USA

**MP-04.01**

A 5-Year Follow Up of the Trans-Obturator Tape as a Means of Surgical Treatment of Stress Urinary Incontinence in an Indian Scenario

Shivadeo Bapat, India

**MP-04.02**

Urethral Bulking Agent Trials: A Review and Comparison of Analysis Methodology Utilized in Trial Outcomes

Gamal Ghoniem, USA

**MP-04.03**

Randomized Control Study of MONARC vs. Tension Free Vaginal Tape Obturator (TVT-O) in the Management of Female Incontinence in Comparison of Medium-Term Cure Rate

Duk-Yoon Kim, South Korea

**MP-04.04**

Comparison of TVT-SECUR and Transobturator Tape for Outcome and Patient Satisfaction in Female Stress Urinary Incontinence

Joon Chul Kim, South Korea



- MP-04.05** Transobturator Suburethral Tape (TOT) vs Single Incision Sling System (TVT-Secur System, TVT-S): Comparison of Efficacy for Mixed Urinary Incontinence  
Gun Nam Kim, South Korea
- MP-04.06** Influences of Preoperative Physical Examination and Urodynamic Study Parameters on Postoperative Voiding Dysfunctions in Patients with Urodynamic Stress Incontinence  
Sung Tae Cho, South Korea
- MP-04.07** TOT Approach in Stress Urinary Incontinence (SUI): Outcome in Obese Female  
Axel Hegele, Germany
- MP-04.08** The Effect of Body Mass Index on the Result of the SPARC in Patients with Stress Urinary Incontinence  
Luck Hee Sung, South Korea
- MP-04.09** The SPARC Procedure for the Treatment of Female Stress Urinary Incontinence in the Elderly  
Luck Hee Sung, South Korea
- MP-04.10** Change of Sexual Function after Midurethral Sling Procedure for Stress Urinary Incontinence  
Duk-Yoon Kim, South Korea
- MP-04.11** Success of Midurethral Slings in Women with Severe Lower Urinary Tract Symptoms  
Howard B. Goldman, USA
- MP-04.12** Force of Stream After Sling Therapy (FAST): Safety and Efficacy of a Rapid Discharge Pathway Based on Subjective Report  
Howard B. Goldman, USA
- MP-04.13** The Early Experience of Simultaneous Transobturator Tape (TOT) and Trocar-Guided Tension Free Vaginal Mesh (Prolift) Procedures in Patients with Stress Urinary Incontinence Concomitant with Anterior Vaginal Wall Prolapse  
Cheol Young Oh, South Korea
- MP-04.14** The Efficacy of Trans-Section of Synthetic Sub-Urethral Sling Tape for Treatment of Obstructive Voiding Symptoms Following Transobturator Sling Surgery After 3 Years' Follow Up  
Gun Nam Kim, South Korea
- MP-04.15** The Management of Midurethral Sling (MUS) Tape Erosion  
Duk-Yoon Kim, South Korea
- MP-04.16** Laparoscopic Artificial Urinary Sphincter Implantation for Female Genuine Stress Incontinence: 5 Years' Experience  
Julien Bacle, France


**MODERATED POSTER SESSION 5  
BPO**
*Room: Karam 2*

 Chairs: Said Moudouni, Morocco  
 JLH Ruud Bosch, Netherlands

**MP-05.01** Comparison of Men with Acute versus Chronic Urinary Retention: Etiology, Clinical Features, Prostatic Volume and Histology

Amir Zarrabi, South Africa

**MP-05.02** Is Prostatic Resistive Index Helpful when Choosing Treatment Option in Patients with Benign Prostate Hyperplasia?

Ali Memis, Turkey

**MP-05.03** Sources of Variability when Using Only Penile Cuff Test (PCT) Can Be Rubbed Out by Combination with 'VBN' Method

Samuel Osaghae, UK

**MP-05.04** Bladder Compliance Is Associated with the Amplitude of Detrusor Overactivity in Men with Symptomatic Benign Prostatic Enlargement Associated with Detrusor Overactivity

Narihito Seki, Japan

**MP-05.05** A Prospective Study on the Management of Bladder Lithiasis: Is Prostatic Surgery a Necessary Adjunct?

Georgios Papadopoulos, Greece

**MP-05.06** Open Prostatectomy Versus Transurethral Resection of the Prostate: Where Do We Stand in the New Era? A Randomized Clinical Trial

Nasser Simforoosh, Iran

**MP-05.07** Transurethral Resection of the Prostate Combined with Holmium Laser Enucleation (omega:wTURP) is Safe and Effective for Treating Benign Prostatic Hyperplasia

Noriaki Tokuda, Japan

**MP-05.08** Holmium Laser Enucleation of the Prostate: Non-Mentor-Aided Learning Curve and Its Proper Estimation

Seung-June Oh, South Korea

**MP-05.09** Treatment of Benign Prostatic Hyperplasia with Plasmakinetic Vaporization: Six-Year Follow-Up

Muhammet Ihsan Karaman, Turkey

**MP-05.10** Is Bipolar Transurethral Resection in Saline (TURis) a Good Alternative for Laser?

Siavash Falahatkar, Iran

**MP-05.11** Intraprostatic Injection of Botulinum Toxin Type-A (Dysport) Relieves Bladder Outlet Obstruction in Men

Stefan Carl, Germany

**MP-05.12** Laser Photovaporisation Prostatectomy (PVP) in High Hemorrhagic Risk Patients

Gerard Cariou, France



**MP-05.13** National Trends in the Surgical Therapy of Benign Prostatic Hyperplasia in the United States (2002-2008)

Sean Elliott, USA

**MP-05.14** Incidence of Urethral Stenosis Using Gyrus Bipolar System: Over 2000 TURP with 5 Years Follow-Up: Critical Review of Our Department Experience

Francesco Pisanti, Italy

**MP-05.15** Diode Laser Enucleation of the Prostate: Preliminary Results of a Novel Technique

Stephen Shei-Dei Yang, Taiwan

#### **MODERATED POSTER SESSION 6 OVERACTIVE BLADDER**

*Room: Karam 3*

Chairs: Sender Herschorn, Canada  
Alan Wein, USA

**MP-06.01** The Association of Nocturia with Sleep Disorders, Metabolic and Chronic Pulmonary Conditions

Kaan Bal, Turkey

**MP-06.02** Oral Desmopressin in the Treatment of Nocturia in an Aging Population

Ahmad Haider, Germany

**MP-06.03** Delayed Development of Hyponatremia in the Patients of Nocturia Managed with Desmopressin Acetate (DDAVP)

Jaeshin Park, South Korea

**MP-06.04** Superior Efficacy of Fesoterodine Over Tolterodine: A Pooled Analysis of 2 Head-to-Head, Placebo-Controlled Trials

Philip Van Kerrebroeck, Netherlands

**MP-06.05** Fesoterodine Versus Tolterodine for Overactive Bladder in Older and Younger Subjects

Paul Abrams, UK

**MP-06.06** The Efficacy of Tolterodine and Tamsulosin Combination Therapy in Female OAB Patients

Heung Jae Park, South Korea

**MP-06.07** Correlation between Overactive Bladder (OAB) Symptoms in Female Patients and Urodynamic (UD) Findings

Ali Al-Zahrani, Canada

**MP-06.08** Correlation between Overactive Bladder (OAB) Symptoms in Men and Urodynamic (UD) Findings

Ali Al-Zahrani, Canada

**MP-06.09** Morbidity of Invasive Urodynamics: Experience after 750 Procedures

Cristian Persu, Romania

**MP-06.10** Prospective Randomized Study for Long Term Efficacy of Percutaneous Tibial Nerve Stimulation (PTNS) in Patients with Refractory Overactive Bladder: Maintenance Protocol

Yasser Farahat, Egypt



**MP-06.11** Evaluation of Long-Term Results of Single Time and Repeated Botulinum-A Toxin (BTX-A) Injections into the Detrusor Muscle for Idiopathic Overactive Bladder Syndrome (OAB)

Carsten Frohme, Germany

**MP-06.12** An Open Label Pilot Study Investigating the Safety and Efficacy of Botox® in 20 Female Patients with Refractory Symptoms of High Urinary Voiding Frequency Without Incontinence

Richard Casey, Canada

**MP-06.13** Outcomes and Complications of Botulinum Toxin-A in Non-neurogenic Detrusor Overactivity Refractory to Anticholinergics

Younès Bayoud, France

**MP-06.14** Sacral Neuromodulation for Double Incontinence: Postoperative Results from the Patient's Perspective

Andreas Petrolekas, Greece

**MP-06.15** The Changes of Overactive Bladder Symptoms after Mid-Urethral Sling Surgery in Patients with Stress Urinary Incontinence Plus Overactive Bladder Symptoms: Long-Term Results

Tae Hyo Kim, South Korea

**MP-06.16** Impact of PDE-5 Inhibitors on Clitoral Blood Flow after Tension-Free Vaginal Tape-Obturator (TVT-O) for Stress Urinary Incontinence

Artur Palmas, Portugal

1600-1730 **Moderated Video Session 2**  
**Various Topics**

*Room: Karam 5*

Chairs: Sanjay Kulkarni, India  
Richard Santucci, USA

1600-1610  
**VID-2.01** 980nm Diode Laser Enucleation of the Prostate (DiLEP)

Oscar Buisan, Spain

1610-1620  
**VID-2.02** Bulkamide Hydrogel: Limits of a New Bulking Agent in the Mini-Invasive Therapy of Incontinence after Prostatectomy

Franco Mantovani, Italy

1620-1630  
**VID-2.03** Reconstructive Urethroplasty Using Porcine Acellular Matrix (S.I.S.): Evolution of the Grafting Technique and Results of 10 Years' Experience

Franco Mantovani, Italy

1630-1640  
**VID-2.04** Purely Transvaginal Excision of Mesh Erosion Involving the Bladder

Howard Goldman, USA

1640-1650  
**VID-2.05** Tissue Activated Laser Beam in the Treatment of Urethral Stricture

Vincent Flamand, France

1650-1700  
**VID-2.06** Combined Perineal-Prerectal Approach and Pedunculated Penile Skin Flap Autoplasty for Complex Bulbar-Membranous Urethral Strictures

Edoardo Austoni, Italy



1700-1710

**VID-2.07**

**Free Preputial Skin Dorsal Onlay Urethroplasty: Our Experience in 104 Patients**

Shivadeo Bapat, India

0900-1600 **Unmoderated Poster Session 2**

*Room: Royale*

**UP-2.01**

**Endoscopic Removal of Spontaneously Migrated IUD to the Bladder**

Edson Retroz, Portugal

**UP-2.02**

**The Effect of Tamsulosin in Female Patients with Lower Urinary Tract Symptoms and Predictive Factors for Therapeutic Outcome: Multicenter, Prospective Study**

Seong Ho Lee, South Korea

**UP-2.03**

**Improvement of Lower Urinary Tract Dysfunction after Trocar-Guided Transvaginal Mesh Repair of Pelvic Organ Prolapse in Elderly Women**

Seung-Ju Lee, South Korea

**UP-2.04**

**Transvaginal Repair of Genital Prolapse with Prolift System: Morbidity and Anatomic Outcomes After 5 Years of Use: A Multicentric Study**

Johann Ménard, France

**UP-2.05**

**Female Urethral Diverticulum and the Result of Surgical Repair**

Farzaneh Sharifiaghdas, Iran

**UP-2.06**

**Vesico-Vaginal Fistulas: Surgical Management in Our Center**

Eva Golmayo Muñoz-Delgado, Spain

**UP-2.07**

**Disorders in Urinary Bladder Micturition After Rectal Operations**

Mustapha Addali, Germany

**UP-2.08**

**TVT vs. TOT: A Comparison of Continence Results, Complications and Quality of Life After a Median Follow-up of 48 Months**

Mustapha Addali, Germany

**UP-2.09**

**Consideration on Surgical Results and Quality of Life in the Surgical Repair of Anterior Vaginal Prolapse**

Tommaso Brancato, Italy

**UP-2.10**

**Midterm Results of Continence, Complications and Quality of Life after TOT Procedure**

Tommaso Brancato, Italy

**UP-2.11**

**A Comparative Analysis of MiniArc™ and Monarc™ Sub-Urethral Slings for Female Stress Urinary Incontinence**

Aaron Brown, UK

**UP-2.12**

**Laparoscopic Sacrocolpopexy: Initial Experience in 10 Cases**

Reynaldo Gómez, Chile

**UP-2.13**

**Characteristics of Lower Urinary Tract Symptoms and Efficacy of the Treatment with Desmopressin in Female Patients**

Hyuk Jin Cho, South Korea



- UP-2.14** The Effects of the REMEEEX System® for Treatment of Re-do Urinary Incontinence and Intrinsic Sphincteric Deficiency  
Hee Chang Jung, South Korea
- UP-2.15** The Effect of Stage II or Less Cystocele on Voiding Pattern after Midurethral Sling  
Hyeong Gon Kim, South Korea
- UP-2.16** The Influence of Obesity on Patients with Female Stress Urinary Incontinence  
Sung-Wghan Jo, South Korea
- UP-2.17** Postoperative Voiding Difficulty after Midurethral Sling Surgery in Female Stress Urinary Incontinence: When Does it Get Better?  
Dong-Hwan Lee, South Korea
- UP-2.18** Evaluation of a Modified Novel Vaginal Flap Operation in Stress Urinary Incontinence (SUI) Using Dynamic MRI  
Abdelaziz Fayed, Egypt
- UP-2.19** Adjustable Devices in the Treatment of Stress Incontinence  
Seshikanth Middela, UK
- UP-2.20** Sacrospinous Ligament Fixation for Vaginal Vault Prolapse with a Reusable Suturing Device (RSD-Ney) in 5 Minutes  
Joerg Neymeyer, Germany
- UP-2.21** Readjustable Sling Procedures for Treatment of in Female Stress Urinary Incontinence with Intrinsic Sphincter Deficiency  
Joon Hwa Noh, South Korea
- UP-2.22** Initial Experience of Cystocele and Stress Incontinence Repair with Prolift System and Concomitant Tension-Free Vaginal Tape (TVT)  
Sung Hyun Paick, South Korea
- UP-2.23** Voiding Pattern after 'U-Method' TVT-Secur: Is it Obstructive?  
Le Mai Tu, Canada
- UP-2.24** TOT Surgery Experience with Unitape-T-Plus Mesh  
Anibal Salazar, Chile
- UP-2.25** Early Urinary Catheter Removal After TOT Procedure: Evaluation of Immediate Postoperative Voiding  
Anibal Salazar, Chile
- UP-2.26** Short-Term Results of Mini-Sling TVT Secure and Rectus Facial Sling Surgery in the Treatment of Female Stress Urinary Incontinence  
Farzaneh Sharifiaghdas, Iran
- UP-2.27** The Effect of Postoperative Physical Activity on the Outcomes of Transobturator Tape Procedure  
Dong-Gil Shin, South Korea



- UP-2.28** Comparison of TOA and TOT for Treating Female Stress Urinary Incontinence: Short-Term Outcomes  
Chong Koo Sul, South Korea
- UP-2.29** Prevalence of Stress Urinary Incontinence in Romania  
Cristian Iulius Surcel, Romania
- UP-2.30** TVT and Vaginal Prolapse: Long-Term Follow Up  
Cedomir Topuzovic, Serbia
- UP-2.31** Is There a Place for Nonsurgical Management of Female Stress Incontinence?  
Cedomir Topuzovic, Serbia
- UP-2.32** Sacrocolpopexy for Pelvic Floor Reconstruction in Pelvic Organ Prolapse Causing Female Stress Urinary Incontinence: First Results of a Minimally Invasive Laparoscopic Approach  
Reinhold Zimmermann, Austria
- UP-2.33** Estimation of Female Urethral Elasticity and Flexibility from Cystourethroscopic Image  
Kohei Horiuchi, Japan
- UP-2.34** Impact on Quality of Life of Botulinum Toxin-A in Non-neurogenic Detrusor Overactivity Refractory to Anticholinergics  
Younès Bayoud, France
- UP-2.35** Total Urgency Score (TUS) as a Measure of Frequency and Urgency in SUNRISE  
Juraj Mikulas, Slovakia
- UP-2.36** Effectiveness and Tolerability of a Combined Medication of Two Different Anticholinergics for the Patients with Symptoms of Overactive Bladder  
Sang Eun Lee, South Korea
- UP-2.37** Impact of Prostate Volume on the Efficacy of Solifenacin Succinate Monotherapy in Men with Lower Urinary Tract Symptoms and Overactive Bladder Symptoms  
Sachi Kitayama, Japan
- UP-2.38** Rate and Predictive Factors of the Anticholinergic Add-On Therapy in Men with Residual Overactive Bladder Symptom after 4 Weeks of  $\alpha$ -Blocker Monotherapy  
Kyu-Sung Lee, South Korea
- UP-2.39** Symptom Change after Discontinuation of Successful Anticholinergic Treatment in Patients with Overactive Bladder Symptoms: Prospective, Randomized, Multicenter Trial  
Kyu-Sung Lee, South Korea
- UP-2.40** Influence of Overactive Bladder on Falls: Study on Females Aged 40 and Older in Urban and Rural Communities  
Hong Yong Choi, South Korea



**UP-2.41** A Comprehensive Patient Support Programme Improves Persistence with Solifenacin in Overactive Bladder (OAB)

Emad Siddiqui, UK

**UP-2.42** Phasic or Terminal Detrusor Overactivity in Women: Age, Urodynamic Findings and Sphincter Behavior Relationships

Samuel Osaghae, UK

**UP-2.43** Nervous Control of Lower Urinary Tract (LUT) During Detrusor Overactivity (DO): An Approach Using Modeled Analysis of Filling Cystometries and Pressure-flow Studies

Samuel Osaghae, UK

**UP-2.44** An Electronic Tool to Support the Selection of Patients with Overactive Bladder Syndrome for Sacral Neuromodulation

Philip Van Kerrebroeck, Netherlands

**UP-2.45** Orthotopic Enterocystoplasty for Bladder Substitution: 120 Cases

Faissal Benlamssouhi, Morocco

**UP-2.46** Why Studer Orthotopic Bladder? Observation of 110 Patients

Dimitar Shishkov, Bulgaria

**UP-2.47** Quality of Life after Orthotopic Urinary Diversion

Sasa Vojinovic, Serbia

**UP-2.48** Long-Term Tolerability and Efficacy of Pentosan Polysulphate Sodium in the Treatment of Patients with Bladder Pain Syndrome (BPS)

Ali Al-Zahrani, Canada

**UP-2.49** Prospective Study on Prostate Biopsy in Patients with High Serum PSA in Consideration of Prostatic Inflammation

In-Rae Cho, South Korea

**UP-2.50** Glycosaminoglycans in Bladder Biopsies and in Urine as Possible Markers for Interstitial Cystitis/Painful Bladder Syndrome

Marcos Lucon, Brazil

**UP-2.51** Comparison of Maki's Technique and Sonication in the Diagnosis of Microbial Ureteral Stent Colonization: A Randomized Prospective Study

Gernot Bonkat, Switzerland

**UP-2.52** The Relationship Between Microbial Ureteral Stent Colonisation and Male Lower Urinary Tract Symptoms

Gernot Bonkat, Switzerland

**UP-2.53** The Correlation Between Post-Void Residual Urine Volume and Urinary Tract Infection in Asymptomatic Men Visited for Prostate Examination

Yong-Hyun Cho, South Korea



**UP-2.54** What Volume of Post-Void Residual Urine Causes Urinary Tract Infection?

Nam Kyu Lee, South Korea

**UP-2.55** Ciprofloxacin in the Treatment of Urinary Tract Infections in General Practice

Mohamed Anis Khelil, Morocco

**UP-2.56** Urogenital Tuberculosis (About 116 Cases)

Mohamed Anis Khelil, Morocco

**UP-2.57** Antimicrobial Effect of Lactobacillus in a Rat Model of Escherichia coli Lower Urinary Tract Infection: A Preliminary Study

Chang Hee Han, South Korea

**UP-2.58** Schistosomiasis: Unusual Cause of LUTS in Europe

Edson Retroz, Portugal

**UP-2.59** Large Retroperitoneal Abscess Complicating Neurogenic Lower Urinary Tract Dysfunction

Emmanuel Patris, Greece

**UP-2.60** Clinical Significance of Postoperative Bacteriuria After Transurethral Surgery: Results of a Prospective Multicenter Study

Andreas Petrolekas, Greece

**UP-2.61** Possibility of Antibiotic Usage According to Their Activity Spectrum and Price for Uncomplicated Urinary Tract Infections on the Primary Level of Healthcare in the Region

Zurab Rainauli, Georgia

**UP-2.62** Intravesical Instillation of Hyaluronic Acid in the Treatment of Recurrent Urinary Tract Infection in Women

Farzaneh Sharifiaghdas, Iran

**UP-2.63** The Role of Neonatal Circumcision in Prevention of Urinary Infection: A Large Prospective Study with Long Term Follow-Up Using Plastibell

Nasser Simforoosh, Iran

**UP-2.64** Perioperative Morbidity and Mortality in Fournier's Gangrene

Cristian Iulius Surcel, Romania

**UP-2.65** Life Saving D-J Stenting in Lower Urinary Tract Infection: Really a Daring Step or Not?

M. Abdul Hamid Umer, Pakistan

**UP-2.66** AUA Recommended Preparations (Antibiotic Prophylaxis and Cleansing Enema) Are Important to Prevent Febrile Complications in Transrectal Ultrasonography Guided Prostate Biopsy

Jae Yong Chung, South Korea



**UP-2.67** Anastomotic Stricture after Radical Prostatectomy (About 7 Cases)

Hassen Khouni, Tunisia

**UP-2.68** Low Power Holmium Laser Urethrotomy Can Be Safely Performed Under Local Anesthesia in Urethral Stricture Patients Following Transurethral Resection of the Prostate

Kang Su Cho, South Korea

**UP-2.69** York Mason Approach: A Good Technique for the Management of Urethrorectal Fistulas

Mouad Statoua, Morocco

**UP-2.70** Incidence of Fossa Navicularis Strictures in Retropubic Radical Prostatectomy

Francesco Pisanti, Italy

**UP-2.71** Substitution Urethroplasty

Deen Sharma, Guyana

**UP-2.72** Urethroplasty in Multiple Stages Using Buccal Mucosa Grafts

Kathy Vander Eeckt, Belgium

**UP-2.73** End-To-End Repair or Augmented Anastomosis for Single-Stage Bulbar Urethroplasty in Short Urethral Strictures?

Kathy Vander Eeckt, Belgium

**UP-2.74** Male Urethral Carcinoma: Does Stricture Urethra / Multiple Instrumentation Predispose It?

Muthu Veeramoni, India

**UP-2.75** Outcome of Daycase Optical Urethrotomy

Adam Farrier, UK

**UP-2.76** A Comparative Study on the Clinical Effects of Silodosin and Naftopidil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

Toshiro Shirakawa, Japan

## 0700-0800 **Surgical Tips: Stress Urinary Incontinence**

*Room: Fès I*

Chair: Gopal Badlani, USA

### 0700-0720 **Preoperative Counseling in Patients with Mixed Incontinence**

Christopher Chapple, UK

### 0720-0740 **Use of Bulking Agents**

Sender Herschorn, Canada

### 0740-0800 **Choice of Material and Procedure Comparison for SUI**

Gopal Badlani

## 0800-1000 **Plenary: Neuro-Urology**

*Room: Ministres*

Chairs: Hassan Shaker, Egypt  
Jean-Jacques Wyndaele, Belgium

### 0800-0820 **Urological Assessment and Management of Congenital Neurological Bladder**

Catherine deVries, USA

### 0820-0830 **Discussion**

### 0830-0930 **Debate: Modern Management of the Neurogenic Bladder Associated with Spinal Cord Injury**

0830-0850 Jean-Jacques Wyndaele

0850-0910 Helmut Madersbacher, Austria

0910-0930 **Discussion**

### 0930-0950 **Complications in Neurogenic Bladder**

David Castro-Díaz, Spain

### 0950-1000 **Discussion**

## 1000-1015 **Break**

## 1015-1215 **Plenary: Female Stress Urinary Incontinence**

*Room: Ministres*

Chairs: Gopal Badlani, USA  
Ahmed Ameer, Morocco

### 1015-1035 **Role of Pelvic Floor Muscle Exercises in the Management of SUI**

Kari Bo, Norway

### 1035-1045 **Discussion**

### 1045-1105 **Role of Urodynamics in the Surgical Management of SUI**

Sherif Mourad, Egypt

### 1105-1115 **Discussion**

### 1115-1135 **Advances in the Management of SUI /POP**

Gopal Badlani

### 1135-1145 **Discussion**

### 1145-1205 **Managing the Complications of Synthetic Tapes for SUI**

Karl Kreder, USA

### 1205-1215 **Discussion**



## 1215-1230 Closing Remarks and Invitation to Berlin 2011

Room: Ministres

Chair: Luc Valiquette, Canada

With: Paul Abrams, UK

Joachim Thüroff, Germany



## 1300-1700 Sponsored Symposium

Room: Fès I

### **AstraZeneca Morocco**

#### **Prostate Cancer Course: Which Treatments Are On Hand in 2010 and Beyond?**

Chairs: Claude Abbou, France

Aziz Akira, Morocco

Richard Fourcade, France

Redouane Rabii, Morocco

### 1300-1310 Introduction

Redouane Rabii

*Locally Advanced Prostate Cancer*

### 1310-1335 Surgical Management

Claude Abbou

### 1335-1355 Radiotherapy Management

Hassan Joughadi, Morocco

### 1355-1420 Hormone Therapy

Richard Fourcade

### 1420-1435 Discussion

## 1435-1450 Break

*Metastatic Prostate Cancer*

### 1450-1510 Hormone Therapy

Richard Fourcade

### 1510-1530 Castration-Resistant Prostate Cancer

Mounir Bachouchi, Morocco

### 1530-1555 Acute Obstructive Anuria

Arthur Smith, USA

### 1555-1615 Bone Metastasis-Related Pain

Rachid Cherkab, Morocco

### 1615-1645 3 Case Studies: Treatment Problems in Routine Practice

Redouane Rabii

Hassan Joughadi

Arthur Smith

### 1645-1700 Closing Remarks

Chairs



*Given space and time constraints, these abstracts could not be scheduled for presentation. Abstracts are listed in order of author's last name.*

**Sex, Sexuality and Procreation in Complex Uro-Genital Anomalies**

Emmanuel Abara, Canada

**Ureterscopy for Treatment of Ureteral Calculi in Children**

Atef Abd Elatif, Egypt

**Single Port Laparoscopic Augmentation Ileocystoplasty: The First Reported Case**

Mahmoud Abdel Hakim, Egypt

**Holmium Laser Enucleation of the Prostate: The Cairo University Experience**

Mahmoud Abdel Hakim, Egypt

**Tumor Treatment in Kidney and Ureter Using the LFD (Leveled Field Density) Laser Therapy with Reduced Zone of Thermal Damage and a Set of High-Energy Flexible Fiber Probes**

Waleed Abdul-Wahab Al-Anari, Germany

**Robot-assisted Laparoscopic Radical Prostatectomy with the daVinci System: Experiences After 1500 Cases**

Mustapha Addali, Germany

**Mature Ovarian Teratoma: An Unusual Cause of Acute Urinary Retention**

Patrick Adegun, Nigeria

**The Correlation Between Diffusion-Weighted Imaging and Histopathological Evaluation of 336 Prostate Biopsy Sites in Patients with Prostatic Disease**

Oztug Adsan, Turkey

**Treatment of Metastatic Hormone Resistant Prostate Cancer (mHRPC) with Docetaxel: Four Years' Experience**

Eduardas Aleknavicius, Lithuania

**Photodynamic Detection of the Tumor Margins During the Nephron-Sparing Surgery**

Denis Altunin, Russia

**Results of Combination Treatment with Adjuvant Photodynamic Therapy (PDT) in Patients with Bladder Cancer**

Denis Altunin, Russia

**Neoadjuvant Chemotherapy with Gemcitabine and Carboplatin Followed by Concurrent Chemoradiotherapy in Locally Advanced Carcinoma of Urinary Bladder**

Tariq Ansari, Pakistan

**Outcome of Renal Function in Retoroperitoneal Laparoscopic Partial Nephrectomy with Ice Slush Cooling**

Toshiki Aoyagi, Japan

**Calcic Nephrolithiasis: A Double-Blind Randomized Study, 2009**

Mirna Caridad Atiés Sánchez, Cuba

**Robotic HIFU: Early Treatment Complications in Prostate Cancer**

Francesco Attisani, Italy



**Long-Term Anatomical and Functional Results of Laparoscopic Promontofixation (LP) for Pelvic Organ Prolapse (POP)**

Julien Bacle, France

**Laparoscopic Partial Nephrectomy: New Method to Evaluate Renal Function Loss**

Fariborz Bagheri, Hungary

**Multiple Laparoscopic Procedures for Removal of Small Renal Cell Cancer and Metachronous Bilateral Adrenal Metastasis**

Fariborz Bagheri, Hungary

**Laparoscopic Sacrocolpopexy for Treatment of Pelvic Organ Prolapse: Our Short-Term Result**

Fariborz Bagheri, Hungary

**Endoscopic Laser Core Through Lower Ureter with Bladder Cuff During Nephro-ureterectomy in Upper Tract TCC - A Point of Technique**

Shivadeo Bapat, India

**Standard vs. Variant Vascular Procedures in Renal Allograft Implantation**

Dragoslav Basic, Serbia

**Bone Anchoring Sling Using Autologous Aponeurosis for Male Incontinence**

Abbas Basiri, Iran

**Establishing a Community-Based Robotics Program**

Marc Beagler, USA

**Anatrophic Nephrolithotomy (A Series of 56 Cases)**

Faissal Benlamssouhi, Morocco

**Retroperitoneal Laparoscopic Adrenalectomy for Cushing's Syndrome**

Faissal Benlamssouhi, Morocco

**Does Stage pT0 Cystectomy Specimen Confer a Survival Advantage in Patients with Minimally Invasive Bladder Cancer?**

Abderrazek Bouzouita, Tunisia

**Late Period Complication After Inguinal Hernia Repair: A Case Report**

Ahmet Camtosun, Turkey

**Variations of Prostate Specific Antigen Level According to Histologic Results 3 Months after Transurethral Prostatectomy**

Kang Su Cho, South Korea

**Effect of Alpha-Blocker and Anticholinergic Drugs on Lower Urinary Tract Symptoms (LUTS) Related to Ureteroscopic Surgery and Ureteral Stent Indwelling for Ureter Stones**

Sung Tae Cho, South Korea

**The Factors Affecting on the Decision of the Surgical Treatment in Patients with BPH**

Seong Choi, South Korea

**Treatment of Difficult Recurrent Urethral Stricture Using Dorsal Onlay Urethroplasty with Buccal Mucosa Graft: Experiences and Short-Term Results of Two Cases**

Jae Yong Chung, South Korea

**The Burden of Wild Screening for Prostate Cancer at a Nation-Wide Level**

Jean-Nicolas Cornu, France



**Urodynamic Study in Lower Urinary Tract Dysfunction (Neurogenic Bladder)**

Mohammad Reza Darabi Mahboub, Iran

**Micro-Coil Embolisation in High-Flow Priapism: Results and Long-Term Follow Up**

Gunter De Win, Belgium

**High-Intensity Focused Ultrasound (Sonablate 500®) for the Treatment of Prostate Cancer: Trifecta Outcomes**

Louise Dickinson, UK

**Versus Conventional Surgery Laparoscopic Nephrectomy for Benign Diseases of the Kidney**

Salah Elgachbour, Morocco

**Latrogenic Ureteral Trauma: Therapeutic Approach and Place of Ureteroscopy**

Jihad El Ghanmi, Morocco

**Retroperitoneal Laparoscopy Nephrectomy for Pyelonephritic Kidney**

Hamza El Neil, Morocco

**Laparoscopic Treatment for Renal Hydatid Cyst Using a Retroperitoneal Approach: An Initial Experience**

Hamza El Neil, Morocco

**Retroperitoneal Laparoscopic Nephrectomy for Giant Hydronephrosis**

Hamza El Neil, Morocco

**Laparoscopic Drainage of Abscess of Psoas: Two Cases**

Hamza El Neil, Morocco

**Laparoscopic Cystectomy by a Single Incision (LESS)**

Hamza El Neil, Morocco

**Hemangioma of the Spermatic Cord**

Hamza El Neil, Morocco

**Renal Hydatid Cyst: A Negative Serology (About 4 Cases)**

Hamza El Neil, Morocco

**Place in the Balance Cystoscopy Extension of Neo Cervical**

Hamza El Neil, Morocco

**Surgical Treatment of Renal Hydatid Cyst Retroperitoneal: Laparoscopic Versus Open Surgery**

Hamza El Neil, Morocco

**Laparoscopic Treatment of Retroperitoneal Fibrosis**

Hamza El Neil, Morocco

**Penile Prosthesis: First Moroccan Experience**

Hamza El Neil, Morocco

**Forgotten Ureteral Stent: A Case Report**

Hamza El Neil, Morocco

**Vascular Complications of Pheochromocytoma Report of Two Cases**

Issam Elouakili, Morocco

**Pediatric Laparoscopic Orchidopexy: A Novel Mentorship-Training Model for Basic Laparoscopic Surgical Skills**

Dean Elterman, Canada



**Nitrous-Oxide (N<sub>2</sub>O) Induced Near-Field Change in Patients Undergoing HIFU Treatment for Localized Prostate Cancer**

Dean Elterman, Canada

**Anatomical and Functional Results of Prosthetic Trans-Gluteal Apogee®**

Saâd Ed-Dine Fadli, France

**Anatomical and Functional Results of the Transobturator Prosthesis Perigee®**

Saâd Ed-Dine Fadli, France

**Is Complete Supine Percutaneous Nephrolithotripsy (csPCNL) Feasible in Obese Patients?**

Siavash Falahatkar, Iran

**Complete Supine Percutaneous Nephrolithotomy in Patients With and Without a History of Open Stone Surgery: The Time for Change from Prone to Supine Position has Come!**

Siavash Falahatkar, Iran

**Using Ligasure System for Transperitoneal Laparoscopic Nephrectomy and Renal Pedicle Control**

Siavash Falahatkar, Iran

**Kidney Displacement in Complete Supine Percutaneous Nephrolithotripsy is Lower than Prone PCNL (The First Randomized Clinical Trial)**

Siavash Falahatkar, Iran

**Totally Ultrasound vs. Fluoroscopically Guided Complete Supine Percutaneous Nephrolithotripsy (First Report)**

Siavash Falahatkar, Iran

**Complete Supine Percutaneous Nephrolithotomy with Lung Inflation Avoids the Need for a Supracostal Puncture**

Siavash Falahatkar, Iran

**Is Complete Supine Percutaneous Nephrolithotripsy Feasible in all Patients?**

Siavash Falahatkar, Iran

**Plication of the Renal Pelvis: A Simple Alternative to Laparoscopic Pyeloplasty**

Marcelo Featherston, Argentina

**LESS Radical Nephrectomy**

Vincent Flamand, France

**V-Lock® for Hemostasis and Reconstruction in Minimally Access Partial Nephrectomy**

Vincent Flamand, France

**LESS Partial Nephrectomy: Initial Experience Using the Gelpoint® as Access Platform**

Vincent Flamand, France

**Laparoscopic Retroperitoneal Lymph Node Dissection for Renal Cancer Metastasis**

Vincent Flamand, France

**High Risk Prostate Cancer in Laparoscopically Treated Localized Prostate Carcinoma**

Vincent Flamand, France

**Laparoscopic Radical Cystectomy and Neoadjuvant Chemo-Therapy in Invasive Bladder Carcinoma: Initial Experience**

Vincent Flamand, France



**LESS Radical and Partial Nephrectomy Compared to the Conventional Laparoscopic Approach**

Vincent Flamand, France

**Oncologic Results for Extraperitoneal Versus Transperitoneal Radical Prostatectomy**

Vincent Flamand, France

**Partial Nephrectomy: Evaluation of Mid-Term Oncological Results**

Vincent Flamand, France

**Chemotherapy for Bladder Cancer in a Department of Urology: Is It Possible?**

Anis Gamoudi, Tunisia

**Uterine Preservation: Bilateral Sacrospinous Suspension Using Mesh (Uphold®)**

Gamal Ghoniem, USA

**Giant Diverticula of the Urethra with Stones after Endoscopic Urethrotomy**

Omar Ghoundale, Morocco

**Hypospadias Cripples: Staged Buccal Mucosa Graft Repair**

Constantin Gingu, Romania

**Urethrectomy for Urethral Urothelial Tumoral Recurrence Post Radical Cystectomy**

Constantin Gingu, Romania

**Pattern of Organisms Isolated and Antibiotic Sensitivity in Men with Urinary Tract Infections due to Lower Urinary Tract Obstruction at Komfo Anokye Teaching Hospital, Kumasi, Ghana**

Kofi Gyasi-Sarpong, Ghana

**The Assessment of the Effect of Tadalafil on Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia on Patients Treated with Standard Medication**

Ali Hamidi Madani, Iran

**Randomized Controlled Trial of the Efficacy of Isosorbide Addition to Current Treatment in Medical Expulsive Therapy for Ureteral Calculi**

Ali Hamidi Madani, Iran

**The Efficacy of Epidural Ketamine on Shivering during Transurethral Resection of the Prostate under Epidural Anesthesia**

Dong Youp Han, South Korea

**Percutaneous Nephrolithotomy: Comparison of Telescopic and Cone-Tip Metallic Dilator**

Mohammad Mehdi Hosseini, Iran

**Efficiency of Periprostatic Infiltration During Prostatic Biopsy**

Larbi Housseem, Tunisia

**Neoadjuvant Hormonal Treatment did not Improve the Outcome in Locally Advanced Prostate Cancer After Radical Prostatectomy: A Multi-Center Experience**

Chao-Yu Hsu, Belgium

**Non-Disease-Related Prognostic Factors in Locally Advanced Prostate Cancer: A Multi-Center Experience**

Chao-Yu Hsu, Belgium

**Volatile Organic Compounds in Urine: Potential Biomarkers in Bladder Cancer Detection**

Emmanuel Johnson, UK



**Oncological Outcomes after Radical Prostatectomy in Locally Advanced Prostate Cancer: A Multi-Center Experience**

Steven Joniau, Belgium

**Prognostic Factors for Locally Advanced Prostate Cancer: A Multi-Center Experience**

Steven Joniau, Belgium

**The Leptin Concentrations in Seminal Plasma of Normozoospermic, Asthenozoospermic and Oligoasthenozoospermic Men: Its Relationship to Semen Parameters**

Seyed Gholam Ali Jorsaraei, Iran

**Changes of the Anatomical Nomenclature in Urogenital System**

David Kachlik, Czech Republic

**Fiducial Markers for Image Localization Guidance in Prostate Gland Radiotherapy**

Amir Kaisary, UK

**Postprostatectomic Rrethral Stricture Patients**

Cengiz Kara, Turkey

**Incidence of Diabetes Mellitus after Extra Corporeal Shock Wave Lithotripsy in Comparison with Control Group in 15 Years Follow-Up**

Fahimeh Kazemi Rashed, Iran

**Laparoscopic Adrenalectomy for Cushing's Syndrome: Retroperitoneal Approach**

Anis Mohamed Khelil, Morocco

**Retroperitoneal Bilateral Schwannoma**

Mohamed Anis Khelil, Morocco

**The Wounds of the Kidney (About 15 Cases)**

Mohamed Anis Khelil, Morocco

**Liposarcoma of the Spermatic Cord: One Case**

Mohamed Anis Khelil, Morocco

**The Role of Laparoscopy in the Management of Sexual Ambiguity**

Mohamed Anis Khelil, Morocco

**Penile Implant: Surgical Technique**

Mohamed Anis Khelil, Morocco

**Laparoscopy in Urology: The Casablanca Experience**

Mohamed Anis Khelil, Morocco

**Retroperitoneoscopic Drainage of a Psoas Abscess (Two Cases)**

Mohamed Anis Khelil, Morocco

**Investigation of the Location of the Ureteral Stone and Diameter of the Ureter in Patients with Renal Colic**

Kikyung Kim, South Korea

**Epidemiologic Study of the Prevalence and Awareness of Cryptorchidism, Hydrocele, and Varicocele in Elementary Schools in Gwangju South Korea**

Ju Sung Kim, South Korea

**The Effects of Combination Perianal-Intraarectal Lidocaine-Prilocaine Cream and Periprostatic Nerve Block for Pain Control during Transrectal Ultrasound Guided Biopsy of the Prostate: A Randomized, Controlled Trial**

Hae Won Lee, South Korea



**Correction of Adult Epispadias After Failed Repair in Childhood**

Marko Majstorovic, Serbia

**Primary Urethral Carcinoma in Females: A Rare Diagnosis**

Brunolf Lagerveld, Netherlands

**Factors in the Learning Curve of Radical Robotic DaVinci Prostatectomy**

Wolfgang Loidl, Austria

**Parenchymatic and Vascular Changes of the Testicle after Endoscopic Treatment of a Kriptorchism**

Irina Lovskaya, Russia

**Peyronie's Disease: Endocavernous Plaque Excision Without Substitutive Graft: Critical 5-Years' Experience**

Franco Mantovani, Italy

**Straightening-Reinforcing Technique for Treatment of Congenital and Acquired Penile Curvature: 10-Year Results of a Simplification**

Franco Mantovani, Italy

**Radical Prostatectomy Cosmetic Outcome: A Patient Preferences Analysis**

Juan Ignacio Martinez-Salamanca, Spain

**Marzouk Double Purpose Penile Skin Flap Technique for the Substitution of Fossa Navicularis and Glanuloplasty in the Treatment of Persistently Recurring Urethral Warts**

Essam Marzouk, Egypt

**Profile of Aberrant Promoter Methylation of GSTPI Gene in Prostate Cancer**

Radu Traian Minciu, Romania

**Reverse-Transcription PCR of PCA3 Gene in the Molecular Detection of Prostate Cancer**

Radu Traian Minciu, Romania

**Kidney Transplantation from Living Donor: Donor Outcomes?**

Ben Slama Mohamed Riadh, Tunisia

**The Effect of Trazosine on Lower Urinary Tract Symptoms and Pain due to Double J-stent, a Placebo-Blind Randomized Clinical Trial**

Gholamreza Mokhtari, Iran

**Micro Invasive Vaginal Tape for Female Stress Urinary Incontinence**

Michel Naudin, Belgium

**Tamulosin Alters Structure of Prostatic Urethra: Observation by Processed Endoscopic Image**

Yukio Naya, Japan

**Flexible Ureteroscopy for Upper Ureteric Calculi in Children**

Rajendra Nerli, India

**Bladder Stone and Vesico-Vaginal Fistula: A Report of Five Cases**

Anani Wencesl Séverin Odzébé, Republic of Congo

**An Entity to Know: The Congenital Cyst of the Seminal Vesicle: About Two Cases**

Fedwa Ouardi, Morocco

**Biochemical Recurrence in Low and Intermediate Risk Prostate Cancer Low According to the Type of Treatment: Radical Prostatectomy or Radiotherapy**

Eva-Victoria Panos, Spain



**The Effects of Estrogen on Neuronal Nitric Oxide Synthase Expression, Endothelial Nitric Oxide Synthase Expression and Vascular Endothelial Growth Factor Expression and on the Histologic Composition of Rat Uterus and Vagina**

Sung-Woo Park, South Korea

**Functional Changes of Orthotopic Neobladder after Radical Cystectomy in Patients Who has Invasive Bladder Cancer: Long-Term Follow Up**

Sung-Woo Park, South Korea

**Usefulness of Unenhanced and Delayed Enhanced CT for Adrenal Adenoma**

Sung-Woo Park, South Korea

**The Influence of Laparoscopic Extraperitoneal Inguinal Hernioplasty on the Postoperative Voiding Functions**

Sung Yul Park, South Korea

**Cowper's Gland Syringocele**

Sorin Titus Patrascoiu, Romania

**Transrectal Ultrasound and Bladder Cancer Detection**

Tomislav Pejic, Serbia

**The Values of Urethral PSA after Radical Prostatectomy**

Tomislav Pejic, Serbia

**Radical Retropubic Prostatectomy and Adjuvant Therapy**

Zoran Filipovic, Serbia

**Urinary Tract Infection in Spinal Cord Injury Patients**

Cristian Persu, Romania

**Human Serum Angiogenin (ANG-0), Prostate Pathology, and Prostate Cancer Progression Risk Groups**

Francisco Pina, Portugal

**Human Serum Adiponectin (ADIPOQ) has Similar Presence Among Different Prostate Pathologies**

Francisco Pina, Portugal

**Treatment of Erectile Dysfunction with a New Natural Drug Composition Based on Tribulus Terrestris, Biovis and Alga Ecklonia Cava in 82 Patients**

Domenico Prezioso, Italy

**Laparoscopy: A Safe Approach for Insertion of Female Artificial Urinary Sphincter in an Obese Patient**

Amrith Rao, UK

**Efficacy of Dutasteride in Men with High Grade Prostatic Intraepithelial Neoplasia: Results of a Prospective Randomized Placebo Controlled Study**

Andreas Reissigl, Austria

**Bladder Endometriosis Presenting as a Vesical Mass**

Maghsoudi Robab, Iran

**Relationship study between platelet count and stage and grade of renal cell carcinoma in indoor patients**

Mohammad Salehi, Iran

**Urinary Continence after Open versus Laparoscopic Radical Prostatectomy During the Initial Learning Curve**

Misael Santos, Brazil



**The Effect of Arterial Stiffness on Erectile Dysfunction in Patients with Metabolic Syndrome**

Youngjun Seo, South Korea

**PCA3: A New Tool to Diagnose Prostate Cancer and Provide Guidance in Biopsy Decisions**

Giuseppe Sepe, Italy

**Indole-3-Carbinol and Epigallocatechin 3-Gallate in the Treatment of Prostatic Intraepithelial Neoplasia**

Olesya Shkabko, Russia

**Hormone Refractory Prostate Cancer: Is it a Neuroendocrine Tumor?**

Olesya Shkabko, Russia

**Inflammatory Myofibroblastic Tumour of the Bladder: An Enigmatic Cause of Lower Urinary Tract Symptoms**

Shaun Smit, South Africa

**Anchor Tissue Retrieval Bag For Robot-Assisted Laparoscopic Prostatectomy (RALP)**

Kurt H. Strom, USA

**Recurrence Rates Following Percutaneous and Laparoscopic Renal Cryoablation (RC) of Small Renal Masses (SRM): Does the Approach Make a Difference?**

Kurt H. Strom, USA

**Laparoscopic Partial Nephrectomy Versus Renal Cryoablation: A Multicenter Comparison of Intermediate Oncologic Outcomes**

Kurt H. Strom, USA

**Comparing the daVinci Si™ and daVinci S™ Robot Surgical Systems: Is There a Difference?**

Kurt H. Strom, USA

**Early Ambulation Following Robot-Assisted Laparoscopic Radical Prostatectomy (RALP): Is Pharmacologic Thromboembolic Prophylaxis Necessary?**

Kurt H. Strom, USA

**Baseline Sexual Health Inventory for Men (SHIM) Predictive of Erectile Function Following Robot Assisted Laparoscopic Prostatectomy (RALP)**

Kurt H. Strom, USA

**Metastatic Survey for Clinically Low-Risk Prostate Cancer: Is There an Indication?**

Kurt H. Strom, USA

**Does Body Mass Index (BMI) Affect the Clinical Outcomes of Robot-Assisted Laparoscopic Prostatectomy (RALP)?**

Kurt H. Strom, USA

**Early Urethral Catheter Removal Following Robot-Assisted Laparoscopic Prostatectomy (RALP)**

Kurt H. Strom, USA

**Is Prostate Cancer Pathology Following Robot-Assisted Laparoscopic Prostatectomy (RALP) Accurately Predicted by Transrectal Ultrasonographic (TRUS) Guided Biopsy Specimens?**

Kurt H. Strom, USA



**Predictive Factors Assessment for Prostatic Involvement by Transitional Cell Carcinoma of the Bladder Using Clinicopathological Characteristics of the Bladder Tumor**

Ali Tabibi, Iran

**The Evaluation of Y Chromosome Microdeletion in Males with Severe Oligospermia or Azospermia**

Rahim Taghavi, Iran

**Comparing PSA & Free PSA Serum Levels in Fresh and Frozen Blood**

Rahim Taghavi, Iran

**Management of Hidden or Buried Penis in Adults**

Britton E. Tisdale, USA

**The Results of Transurethral Treatment to the Boy of Nocturnal Enuresis Accompanied by Lower Urinary Tract Obstruction**

Masayuki Tsugaya, Japan

**Single Stage Repair of Complex Urethral Distraction Defects with Tubularised Prepuccial Island Flap (TPIF)**

Muthu Veeramoni, India

**The Efficacy and Safety of Transurethral Vaporization Electrocauterization for BPH Patients Concomitant Diabetes Mellitus**

Xiaoqing Wang, China

**Behavior and Medicine Treatment of Urinary Incontinence or Overactive Bladder in Patients after TURP**

Yanbo Wang, China

**Effects of Body Mass Index on Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia Patients**

Yanbo Wang, China

**Laparoscopic Surgery in Abnormality of the Urinary System**

Reinhard Wimhofer, Austria

**Robot-Assisted Laparoscopic Prostatectomy (RALP): Initial Single Surgeon Outcomes**

Carson Wong, USA

**Seminal Vesicle Diameter Predicts Prostate Biopsy Outcome in Men with PSA Between 4 and 10 ng/ml**

Scott Zeitlin, USA




# EXHIBITORS

## COMPANY BOOTH

AMERICAN MEDICAL SYSTEMS	A13
ASTELLAS PHARMA INC.	A1
ASTRAZENECA	A20
COOK MEDICAL	A10
DALE MEDICAL PRODUCTS, INC.	B14
DIREX-INITIA	A14
EDAPTMS	B13
EMS-ELECTRO MEDICAL SYSTEMS	B1
GLAXOSMITHKLINE MAROC	B3
GRUPO TECNIMEDE	B5
LABORIE	A17
LIFE-TECH INC.	B2
MEDITEC	A22
OLYMPUS MEDICAL	B15
PFIZER INC.	B7
PHARMACEUTICAL INSTITUTE (PHI)	A21
PROUS SCIENCE (THOMSON REUTERS)	A19
SHENZHEN HUIKANG MEDICAL APPARATUS CO., LTD.	A11
SIEMENS AG	A15
SILIMED	B6
SOCIÉTÉ INTERNATIONALE D'UROLOGIE	A23
STELLA PERFORMANCE LIMITED	B4
STORZ/ERAMEDIC	B16
STORZ MEDICAL AG	B12
TRIMEDYNE, INC.	A12

At time of print.





## AMERICAN MEDICAL SYSTEMS

A13

10700 Bren Road West  
 Minnetonka, MN 55343  
 USA

Lisa Dahlstrom  
 Tel: 952-930-6000  
 Fax: 952-930-6462  
 info@AmericanMedicalSystems.com  
 www.AmericanMedicalSystems.com

For more than 35 years, American Medical Systems® has provided world-class medical devices used for treating pelvic health issues. Over the past decade, our reputation for quality and medical efficacy has broadened to encompass both devices and therapies that restore pelvic health for men and women. The medical conditions our solutions address include male and female urinary incontinence, erectile dysfunction, prostate disorders (including BPH), urethral strictures, pelvic organ prolapse and fecal incontinence.

## ASTELLAS PHARMA INC.

A1

2-3-11, Nihonbashi-Honcho, Chuo-ku  
 Tokyo 103-8411  
 Japan

Yukiko Nakajima  
 Tel: 81-3-3244-3000  
 yukiko.nakajima@jp.astellas.com  
 www.astellas.com/en

Astellas is committed to making a difference in Urology, from basic research into the human genitourinary system and various urologic disease processes to in-depth understanding about how different urological conditions affect quality of life. Our comprehensive understanding shapes our commitment to patients suffering from urologic conditions and to the medical professionals who treat them.



## ASTRAZENECA

A20

Casablanca Business Center  
 Lotissement Mandarouna 300  
 Sidi Maarouf  
 Casablanca – 20 270  
 Morocco

Taha Aithanine  
 Tel: 00212 5 22 78 91 81 / 00212 6 79 82 80 82  
 Fax: 00212 5 22 78 61 18  
 taha.aithanine@astrazeneca.com  
 www.astrazeneca.com

As a global biopharmaceutical company, our activities touch many people's lives.

For patients and physicians, we provide medicines for some of the world's most serious diseases.

For the people who pay for healthcare, we work to make sure that our medicines offer real value for money.

For our employees, we provide a culture in which they can feel appreciated, energised and rewarded for their contribution.

For our shareholders, we aim to deliver value through our continued focus on innovation and running our business efficiently.

For the wider community, we want to be valued for the contribution our medicines can make to society and trusted for the way in which we do business.

We work closely with all these groups to gain the insights we need to maintain a flow of life-changing medicines that make a real difference for patients in the fight against disease and which add value for our stakeholders and society.

## COOK MEDICAL

A10

O'Halloran Road, National Technology Park  
 Limerick, Ireland

Karen Gough  
 Tel: 353-61-250-551  
 Fax: 353-61-239-420  
 karen.gough@cookmedical.com  
 www.cookmedical.com

Cook Medical integrates device design, biopharma, gene and cell therapy and biotech to enhance patient safety and improve clinical outcomes in the fields of aortic intervention; interventional cardiology; critical care medicine; gastroenterology; radiology, peripheral vascular, bone access and oncology; surgery and soft tissue repair; urology; and assisted reproductive technology, gynecology and high-risk obstetrics. For more information, visit [www.cookmedical.com](http://www.cookmedical.com)


**DALE MEDICAL PRODUCTS, INC. B14**

7 Cross Street  
Plainville, MA 02762  
USA

Alyssa Baine  
Tel: 800-343-3980  
Fax: 508-695-6587  
alyssa@mmcom.com  
www.dalemed.net

Dale Medical Products, Inc. is committed to manufacturing products designed to save nursing time and reduce skin irritation, while leading to comfortable, trouble-free recovery. Throughout its history, Dale has remained near the top of dealers lists of total quality management and prompt delivery. Dale delivers all sales through distributors and supports distributors with constant personal sales activity, advertising, convention attendance, product sampling, in-service video tapes, EDI capability and bar coding.

**DIREX-INITIA A14**

Blumenstrasse 10,  
Wiesbaden D-65189  
Germany

Bella Friedman  
Tel: 49-180-215-2152  
Fax: 49-180-215-1151  
wbmaster@direxgroup.com  
www.direxgroup.com

Duet Magna combines dual-head SWL and electromagnetic technology.

Dual-head Duet: speed and five-fold kidney damage reduction (U. of Indiana research)

Magna: modularity and flexible electromagnetic features, separate or simultaneous dual-heads operation, a wide energy range with electrohydraulic-like performance at high end, a high quality range of fluoroscopy and ultrasonic imagers.



## EDAP TMS

B13

4 rue du Dauphiné  
Vaulx-en-Velin 69120  
France

Maude Pavageau  
Tel: 33-0-472-1531-50  
Fax: 33-0-472-1531-51  
mpavageau@edap-tms.com  
www.edap-tms.com

EDAPTMS is the leader in therapeutic ultrasound. Having been present in the market for more than 30 years, EDAP TMS (NASDAQ: EDAP) develops minimally-invasive therapeutic solutions for urology. As a pioneer and key player in the field of extracorporeal lithotripsy, EDAP TMS introduced the first modular lithotripter and owns the patent for Electroconductive® technology, utilized in its Sonolith® range of ESWL systems.

## EMS-ELECTRO MEDICAL SYSTEMS B1

Chemin de la Vuarpillière 31  
Nyon 1260  
Switzerland

Inka Pawlitzki  
Tel: 41-22-99-44-700  
Fax: 41-22-22-99-44-701  
welcome@ems-ch.com  
www.ems-medical.com

EMS manufactures and markets the Swiss LithoClasT® Master, an endoscopic lithotripter which combines ultrasound and LithoClasT® lithotripsy in one device for single or simultaneous use. Since 2005 the Swiss LithoClasT® 2, successor of the classic Swiss LithoClasT®, has also successfully been introduced to the market.

## GLAXOSMITHKLINE MAROC

B3

42-44 Angle Bd Rachidi & Rue Abou Hamed Al Ghazali  
Casablanca  
Morocco

Abdouh Jalal  
Group Product Development Manager  
Mohamed Janah  
Marketing Director Morocco  
Tel: 212-661-2974-66 / 212-522-4800-02  
Fax: 212-522-4800-41  
abdouh.a.jalal@gsk.com  
mohamed.a.janah@gsk.com  
www.gsk.com

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

GlaxoSmithKline Morocco was created in 2001 through the merger of SmithKline Beecham (Morocco) and GlaxoWellcome (Morocco), and is the second largest pharmaceutical company in Morocco today.



## GRUPO TECNIMEDE

B5

3, rue Bab Mansour, immeuble D  
5ème étage N° 18  
Casablanca 20053  
Morocco

Namly Faycal Ahmed  
Tel: 212-522-39-47-50 / 52  
Fax: 212-522-39-47-42  
f.a.namly@tecnimedemaroc.com  
www.grupotecnime.de.com

Grupo Tecnimed is dedicated to the improvement and preservation of human life and health through the development and commercialization of pharmaceutical products with strong focus on quality and technological innovation.

Grupo Tecnimed produces drugs in several therapeutic areas including Cardiology, Urology, Oncology, Respiratory, Rheumatology and the central nervous system.

All people at Grupo Tecnimed are “Driven by quality. Devoted to life”.

## LABORIE

A17

6415 Northwest Drive, Unit 10  
Mississauga, ON L4V 1X1  
Canada

Shannon Aharonian  
Tel: 905-612-1170 ext. 2262  
Fax: 905-612-0481  
marketing@laborie.com  
www.laborie.com

LABORIE, the worldwide industry leader in urodynamics, is pleased to provide you with the most advanced solutions in Pelvic Floor Dysfunction Management. LABORIE is committed to bringing you the most innovative products: from private offices to world class research institutions, our solutions are designed to expand with your practice.

## LIFE-TECH, INC.

B2

13235 N. Promenade Blvd.  
Stafford, TX 77477  
USA

James Dickens  
Tel: 281-491-6600  
Fax: 281-491-7197  
info@life-tech.com  
www.life-tech.com

Life-Tech is celebrating 40 years of providing unparalleled urodynamic systems and support. We will be featuring the new NovaFlo wireless uroflowmeter. NovaFlo offers convenient and cost-effective screening for voiding dysfunction and post procedure assessment. Our latest Urolab<sup>®</sup> and Urovision<sup>®</sup> urodynamic systems with an EHR interface meet the needs of solo practitioners, group practices and university research centers around the world.



## OLYMPUS MEDICAL

B15

Keymed House Stock Road  
Southend on Sea, Essex SS2 5QH  
United Kingdom

Peter Hawkins  
Tel: 44-0-1702-616-333  
Fax: 44-0-1702-465-677  
info@olympus.co.uk  
www.olympus.co.uk

Olympus enjoys an unparalleled reputation among the world's leading companies in the surgical arena and offers high-quality hybrid rod lens systems or distal video chip technology for cystoscopy, endourology and laparoscopy.

Whatever your urological needs – from lasers to ureteroscopes, laparoscopes to stents – Olympus Medical is the total procedural solution.

## PFIZER INC.

B7

235 E. 42nd Street  
New York, NY 10017  
USA

Ashley Arnold  
Tel: 212-733-8892  
Fax: 646-348-8209  
Ashley.Arnold@pfizer.com  
www.pfizer.com

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

## PHARMACEUTICAL INSTITUTE

A21

Ain El Aouda (Region Rabat)  
Ain El Aouda, BP 4491-I I 850  
Morocco

Nadia Massioui  
Tel: 212-53-7748-284  
Fax: 212-53-774-8639  
contact@phi.ma  
www.phi.ma

The world of medicine in Morocco is changing with the advent of compulsory health insurance and the democratization of access to care. The Pharmaceutical Laboratory Institute (PHI) has responded by launching its own range of generic drugs especially for chronic diseases and cancers. Since 1988, its partnerships with big names in the global pharmaceutical industry have made PHI a Moroccan laboratory standard of multinationals.



## PROUS SCIENCE, A THOMSON REUTERS BUSINESS

A19

Provenza 388, 2nd Floor  
Barcelona 08025  
Spain

Alex de Novoa  
Tel: 34-93-4592-220  
Fax: 34-93-4581-535  
www.prous.com  
www.ttmed.com/urology

Prous Science, a Thomson Reuters business, is a broad-scope international company whose core business is information management and dissemination in the field of medicine and life sciences. TTMed Urology is Thomson Reuters' medical education online resource providing interactive debate, information exchange and educational activities for healthcare professionals worldwide. TTMed Urology is scientifically directed by an editorial board of international KOLs.

## SHENZHEN HUIKANG MEDICAL APPARATUS CO., LTD.

A11

IF, Building C, Yingdali Science and Technology Park,  
No.8 Hongmian Road, Futian Bonded Area  
Shenzhen, 518038  
China

Candy Meng  
Tel: 86-755-25931606  
Fax: 86-755-25515362  
candy@eswl.cn  
www.eswl.cn

Huikang is ISO9001 certified and most of its products are CE approved. Ever since its foundation in 1996, Huikang has dedicated itself to the research, manufacturings and sales of Extracorporeal Shockwave Lithotripter and Extracorporeal Shockwave Therapy which are widely used in calculus treatment and orthopaedics. After a decade of development, Huikang has grown to be No.1 in domestic ESWL industry. Furthermore Huikang has its own professional after-sale team for customers at home and overseas.



## SIEMENS AG

A15

Henkestraße 127  
Erlangen D-91052  
Germany

Dr. Walter Folberth  
Tel.: 49-9131-84-3030  
Fax: 49-9131-84-8456  
walter.folberth@siemens.com  
www.siemens.com/healthcare

Siemens Healthcare is a trendsetter in medical imaging, laboratory diagnostics, medical IT and hearing aids. Siemens offers products and solutions for the entire range of patient care – from prevention and early detection to diagnosis, treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. For further information please visit: [www.siemens.com/healthcare](http://www.siemens.com/healthcare).

## SILIMED

B6

Rua Figueiredo Rocha, 374 Vigarão Geral  
Rio de Janeiro 21240-660  
Brazil

Catarina Lopes  
Tel: 55-21-3687-7108  
Fax: 55-21-3687-7140  
catarinalopes@silimed.com.br  
www.silimed.com.br

Since 1978, SILIMED has had a natural inclination to service the field of plastic surgery, specifically in the sense of making available products of the highest quality. To this end, we have developed the best partnerships with both technology and raw-materials suppliers of the highest quality, and with regulatory bodies.

As a result of this work, we are renowned in more than 60 countries.



## SOCIÉTÉ INTERNATIONALE D'UROLOGIE

A23

1155 University, Suite 1155  
Montreal, QC  
Canada H3B 3A7  
Tel: 514-875-5665  
Fax: 514-875-0205

[www.siu-urology.org](http://www.siu-urology.org)

The SIU is the world's only truly international professional organization serving the global community of urologists.

The Society's mission is to enable urologists in all nations, through international cooperation in education and research, to apply the highest standards of urological care to their patients.

Visit our booth to learn more about future SIU Congresses, including the upcoming 31st Congress of the SIU, October 16-20, 2011 in Berlin, Germany.

## STELLA PERFORMANCE LIMITED B4

PO Box 4276  
Mount Maunganui 3149  
New Zealand

Justine Beale  
Tel: 64-7-575-3730  
Fax: 64-7-575-3760  
[justine@stella-performance.com](mailto:justine@stella-performance.com)  
[www.stella-performance.com](http://www.stella-performance.com)

Stella5 is a revolutionary disinfection system for medical instruments. It offers flexibility in workflow management by enabling faster instrument turnaround within outpatient facilities. This low cost system is especially suitable for cystoscopes and ultrasound probes. Stella5 is battery operated and portable yet it provides the fundamental functions of an Automated Endoscope Reprocessor such as the recording of a comprehensive audit trail.



## STORZ/ERAMEDIC

B16

246, Bld Mohammed-V  
Casablanca  
Morocco

Amal Guennoun  
Tel: 00 212 522 30 69 21  
Fax: 00 212 522 30 83 05  
amal.guennoun@eramedic.com  
www.karlstorz.com  
www.eramedic.com

Karl Storz, founded in 1945, is a leader in endoscopy, development in medical technology research, and is present in all continents.

ERAMEDIC, a subsidiary of COFIMAG is the exclusive distributor of Karl Storz in Morocco, and stands for over 34 years on the market of medical devices. ERAMEDIC is a member of the Global Compact and the first company to have obtained the CGEM label.

## STORZ MEDICAL AG

B12

Lohstampfstrasse 8  
Tägerwilen 8274  
Switzerland

Tel: 41-0-71-677-4545  
Fax: 41-0-71-677-4505  
info@storzmedical.com  
www.storzmedical.com

Established in 1987, STORZ MEDICAL AG is a Swiss member company of the KARL STORZ Group. STORZ MEDICAL shock wave systems have not only proved their efficacy in stone disintegration in millions of cases worldwide, but also for the treatment of Chronic Pelvic Pain Syndrome (CPPS) and Induratio Penis Plastica (IPP).

## TRIMEDYNE, INC.

A12

25901 Commercentre Dr.  
Lake Forest, CA 92630  
USA

Brian Kenney  
Tel: 949-300-6205  
Fax: 949-855-8206  
btkenney@aol.com  
lporterfield@trimedyne.com  
www.trimedyne.com

Trimedyne is a USA-based manufacturer of holmium lasers and patented spinal laser needles, designed to be applied to ablate and reshape spinal disk tissues including nucleus, annulus and bone.



MARRAKECH 2010



LAST NAME	FIRST NAME	PAPER REF	DISCLOSURE
Abdel Hakim	Mahmoud	POD-2.07	Nothing to Disclose
Abrams	Paul	MP-06.05, SPC	Consultant, Speaker (current) - Astellas; Consultant (current) - Pfizer, ONO, Novartis
Addali	Mustapha	UP-2.07, UP-2.08	Nothing to Disclose
Adsan	Oztug	MP-05.02	Nothing to Disclose
Akporiaye	Leslie	PAUSA1	Nothing to Disclose
Ali	Mohamed Hassan	MP-01.05, UP-1.01 UP-1.02	Nothing to Disclose
Alj	Ahmed	AMU3	Not Received
Alnajjar	Hussain	UP-1.29	Nothing to Disclose
Ameur	Ahmed	PL09, SPC	Not Received
Alzahrani	Ali	MP-06.07, MP-06.08 UP-2.48	Nothing to Disclose
Ambu	Alessandra	VID-1.01	Nothing to Disclose
Arrowsmith	Steve	PL02, ST01, VVFC	Nothing to Disclose
Arvanitakis	Thomas	UP-1.73	Nothing to Disclose
Austoni	Edoardo	VID-2.06	Nothing to Disclose
Bacle	Julien	MP-04.16	Nothing to Disclose
Badlani	Gopal	PL09, ST03	Scientific Study, Co-Investigator (1 year) - AMS, Allergan, Pfizer
Bagner	Jens-Willem	MP-03.01	Nothing to Disclose
Bal	Kaan	MP-06.01, UP-1.03	Nothing to Disclose
Bapat	Shivadeo	MP-04.01, VID-2.07	Nothing to Disclose
Barjani	Faycal	AMU3	Not Received
Bauer	Ricarda M.	POD-1.03 POD-1.09 POD-2.09	Speaker, Travel Sponsored (last 2 years) - American Medical Systems, Astellas
Bayoud	Younès	MP-06.13, UP-2.34	Nothing to Disclose
Belahnech	Zakaria	PL02, SPC	Invitation (Nov 2009) - Pfizer
Bencheckroun	Abdellatif	AMU1	Nothing to Disclose
Benhatchi	Nordine	UP-1.04	Nothing to Disclose
Benlamssouhi	Faïssal	UP-2.45	Not Received
Bizic	Marta	MP-02.12	Not Received



LAST NAME	FIRST NAME	PAPER REF	DISCLOSURE
Bo	Kari	PL09	Nothing to Disclose
Bonkat	Gernot	UP-2.51, UP-2.52	Nothing to Disclose
Bosch	J.L.H.Ruud	PL01	Research Funds (2009-2011) - Ferring AG
Bowa	Kasonde	PL04	Nothing to Disclose
Brancato	Tommaso	UP-2.09, UP-2.10	Invitation to SIU 2010 (13-16/10/10) - AMS
Brown	Aaron	UP-2.11	Nothing to Disclose
Bruschini	Homero	MP-03.05, SPC	Nothing to Disclose
Buisan	Oscar	VID-2.01	Not Received
Cariou	Gerard	MP-05.12	Nothing to Disclose
Carl	Stefan	MP-05.11	Nothing to Disclose
Casey	Richard	MP-06.12	Reseacher (2008-present) - Allergan
Castro-Diaz	David	PL08	Advisor, Speaker (2009-2010) - Astellas, Pfizer
Chae	Yunbyung	POD-1.01	Nothing to Disclose
Chapple	Christopher	PL05	Consultant - Pfizer, Astellas, Novartis, Tanabe, Recordati, ONO, Xention, Allergan; Speaker - Pfizer, Astellas; Trial Participation - Pfizer, Astellas, Tanabe, Recordati, Allergan; Research grant - Pfizer, Allergan
Chen	Shiou-Sheng	UP-1.30	Nothing to Disclose
Cheng	Christopher	PL05	Advisory Panel (2010-2012) - Biobot Surgical
Cho	DaeYeon	MP-03.04	Nothing to Disclose
Cho	Hyuk Jin	UP-2.13	Nothing to Disclose
Cho	In-Rae	UP-1.31, UP-2.49	Nothing to Disclose
Cho	Kang Su	UP-1.32, UP-2.68	Nothing to Disclose
Cho	Sung Tae	MP-04.06	Nothing to Disclose
Cho	Yong-Hyun	MP-03.07, UP-2.53	Nothing to Disclose
Choi	Hong Yong	UP-1.42, UP-2.40	Nothing to Disclose
Choi	Jong Bo	UP-1.54	Nothing to Disclose
Choi	Seong	UP-1.33, UP-1.34	Nothing to Disclose
Chung	Jaе Yong	UP-2.66	Nothing to Disclose
Claassen	Frederik	MP-02.09, MP-02.14	Nothing to Disclose



LAST NAME	FIRST NAME	PAPER REF	DISCLOSURE
Cornu	Jean-Nicolas	MP-01.13, MP-01.14 UP-1.36, UP-1.37	Nothing to Disclose
Dabees	Khaled	PAUSA2	TBC - Nothing to Disclose
De Ridder	Dirk	PL02, PL03, ST02 SPC	Advisor, Speaker, Research Funds (ongoing) - American Medical Systems, Astellas
Delmas	Vincent	PL03	Not Received
DeVries	Catherine	PAUSA2, PL08	Nothing to Disclose
Dmochowski	Roger	SPC	Consultant (current) - Astellas, Pfizer, Serenity; Consultant (2008-09) - Medtronic
Doodu-Mante	Sunny	PL04	Consultant urologist (6 years) - Health and Development International
Drake	Marcus	PL01, UROC	Speaker, Advisory, Research (2007-2010) - Astellas; Speaker, Advisory, Research (2006- 2010) - Pfizer; Research (2010) - Allergan; Speaker (2010) - Ferring
Drasa	Kim	MP-03.11	Nothing to Disclose
Eissa	Mohamed	PAUSA2	Nothing to Disclose
El Aidi	Youssef	UP-1.71	Nothing to Disclose
El Ghanmi	Jihad	UP-2.69	FFI (October 13-16, 2010); Pfizer (May 2010)
El Neil	Hamza	UP-1.06, UP-1.07 UP-2.55, UP-2.56	Not Received
Elneil	Sohier	PL02, ST01	Surgical study day (live surgery - one day) - Astellas; Advisor (2010) - Allergan; Advisor (2009-2011) - Medtronic
Elliott	Sean	MP-05.13	Nothing to Disclose
Engelhardt	Paul	UP-1.61	Nothing to Disclose
Falahatkar	Siavash	MP-05.10	Not Received
Farahat	Yasser	MP-02.11, MP-06.10	Nothing to Disclose
Farinha	Rui	UP-1.08	Nothing to Disclose
Farrier	Adam	UP-2.75	Nothing to Disclose
Fayed	Abdelaziz	UP-2.18	Not Received
Fekak	Hamid	AMU2	Not Received
Flamand	Vincent	VID-1.06, VID-2.05	Nothing to Disclose



LAST NAME	FIRST NAME	PAPER REF	DISCLOSURE
Fourcade	Richard Olivier	MP-01.02, MP-01.12 UP-1.09, UP-1.44	Advisor (2008-2010) - GSK; Advisor (2009-2010) - AMS
Fowlis	George	PAUSA1	Nothing to Disclose
Frohme	Carsten	MP-06.11	Nothing to Disclose
Frohneberg	Detlef	AMU1	Nothing to Disclose
Fujisaki	Akiko	UP-1.72	Nothing to Disclose
Ganda	Oumarou Sanda	VVFC	Nothing to Disclose
Gentile	Barbara Cristina	UP-1.10	Nothing to Disclose
Ghoniem	Gamal	MP-04.02, POD-1.06	Speaker, Advisory Board (2 years) - Astellas; Consultant (2 years) - Uroplasty; Advisory Board, Consultant (2 years) - Coloplast; Consultant (3 months) - Boston Scientific
Ghoundale	Omar	UP-1.11, UP-1.62	Nothing to Disclose
Goldman	Howard B.	MP-04.11, MP-04.12 VID-2.04	Consultant and Speaker (current) - Johnson & Johnson
Golmayo	Eva	UP-2.06	Nothing to Disclose
Gómez	Reynaldo	MP-02.13, POD-1.07 POD-2.08, POD-2.11 UP-1.56, UP-1.63 UP-2.12	Nothing to Disclose
Gross	Andreas	PL05	Consultant (2009/10) - Cook, Ireland
Gueye	Serigne	PAUSA2, PL02, ST01 VVFC, SPC	Nothing to Disclose
Guimaraes	Miguel	POD-1.04	Nothing to Disclose
Haddane	Youness	AMU3	Not Received
Haider	Ahmad	MP-06.02	Nothing to Disclose
Hampel	Christian	PL03, ST02	Not Received
Han	Chang Hee	UP-2.57	Nothing to Disclose
Hanus	Tomas	UP-1.12	Nothing to Disclose
Hategekimana	Theobald	VVFC	Not Received
Hegele	Axel	MP-04.07, POD-1.05	Nothing to Disclose
Herschorn	Sender	PL01	Not Received
Heyns	Chris	PL04, POD-2.02	Nothing to Disclose



LAST NAME	FIRST NAME	PAPER REF	DISCLOSURE
Hong	Sung Kyu	UP-1.64	Nothing to Disclose
Horiuchi	Kohei	UP-2.33	Nothing to Disclose
Ignjatovic	Ivan	VID-1.02	Nothing to Disclose
Iuchi	Hirokichi	MP-01.08	Nothing to Disclose
Iwamoto	Teruaki	UP-1.65	Nothing to Disclose
Jha	Akhileshwar	MP-02.10	Nothing to Disclose
Jo	SungWhan	UP-2.16	Nothing to Disclose
Jordan	Gerald	PL07, SPC	Nothing to Disclose
Joual	Abdennabi	AMU1, AMU2, PAUSAI	Nothing to Disclose
Jung	Hee Chang	UP-2.14	Nothing to Disclose
Jung	Jae-Hung	UP-1.35	Nothing to Disclose
Jung	Seil	UP-1.80	Nothing to Disclose
Kadiri	Badreddine	AMU2	Not Received
Kajjoka	Shunichi	MP-03.03	Nothing to Disclose
Kam	Sung Chul	MP-01.06	Not Received
Karaman	Muhammet Ihsan	MP-05.09	Not Received
Karig	Roman	POD-1.02, UP-1.74	Nothing to Disclose
Khalaf	Ismail	PL04	Nothing to Disclose
Khouni	Hassen	UP-2.67	Nothing to Disclose
Kim	Duk-Yoon	MP-04.03, MP-04.10 MP-04.15	Nothing to Disclose
Kim	Gun Nam	MP-04.05, MP-04.14	Nothing to Disclose
Kim	Hyeong Gon	UP-2.15	Not Received
Kim	Hyun Woo	UP-1.14	Nothing to Disclose
Kim	Joon Chul	MP-04.04	Nothing to Disclose
Kim	Jun-Mo	UP-1.67	Not Received
Kim	Sung-Jin	POD-2.03	Nothing to Disclose
Kim	Tae Hyo	MP-01.01, MP-03.12 MP-06.15	Nothing to Disclose
Kim	Won Tae	UP-1.66	Nothing to Disclose
Kim	Young-Joo	POD-2.05, UP-1.38	Nothing to Disclose



LAST NAME	FIRST NAME	PAPER REF	DISCLOSURE
Kitayama	Sachi	UP-2.37	Nothing to Disclose
Klecka	Jiri	UP-1.68	Nothing to Disclose
Kojovic	Vladimir	MP-02.15	Nothing to Disclose
Kreder	Karl	PL06, PL09	Clinical Evaluation Committee (2010-2012) - Medtronic
Kumar	Priyadarshi	POD-1.08	Not Received
Labou	Issa	ST01	Not Received
Lee	Chang-Ho	UP-1.17	Nothing to Disclose
Lee	Dong Ki	POD-2.10	Nothing to Disclose
Lee	Dong-Hwan	UP-2.17	Not Received
Lee	Kyu-Sung	MP-01.09, UP-2.38 UP-2.39	Nothing to Disclose
Lee	Namkyu	UP-2.54	Not Received
Lee	Sang Eun	UP-2.36	Nothing to Disclose
Lee	Seong Ho	UP-1.79, UP-2.02	Nothing to Disclose
Lee	Seung Ryeol	UP-1.39	Not Received
Lee	Seung-Ju	UP-2.03	Nothing to Disclose
Lezrek	Mohammed	AMU2, AMU3	Nothing to Disclose
Lona	Vyas	UP-1.53	Nothing to Disclose
Lucon	Marcos	UP-1.57, UP-2.50	Nothing to Disclose
Madersbacher	Helmut	PL08, POD-2.04	Member - Advisory Boards of Allergan (Switzerland), Apogepha (Germany), Astellas (Austria), and Pfizer (Austria); Company Sponsored Lectures - Astellas (Austria), Montavit (Austria), Dr. Pflieger (Germany) and Rottapharm Madaus (Germany)
Mantovani	Franco	VID-2.02, VID-2.03	Not Received
Marzouk	Mohamed	AMU2	Nothing to Disclose
Menard	Johann	UP-1.18, UP-2.04	Nothing to Disclose
Meziane	Fethi	AMU1, PAUSA1	Nothing to Disclose
Middela	Seshikanth	MP-03.15, UP-2.19	Nothing to Disclose
Mikulas	Juraj	UP-2.35	Not Received



LAST NAME	FIRST NAME	PAPER REF	DISCLOSURE
Min	Seung Ki	UP-1.40	Nothing to Disclose
Miranda	Victor	UP-1.69	Nothing to Disclose
Mourad	Sherif	PL02, UROC, SPC	Advisory Board of AFME for OAB (1 year) - Pfizer; Funded Research on Botox in NDO (ended) - Allergan
Muleta	Mulu	VVFC	Nothing to Disclose
Neymeyer	Joerg	UP-1.43, UP-2.20	Nothing to Disclose
Nickel	J. Curtis	PL06, SPC	Consultant, Investigator (2010) - GSK, Pfizer, Watson, Johnson & Johnson, Taris; Consultant (2009) - Ortho Women's Health, Trillium Therapeutics; Consultant (2010) - Farr Labs, Astellas
Noh	JoonHwa	UP-2.21	Nothing to Disclose
Nordling	Jørgen	PL06	Advisor (2009-2010) - Pfizer; Advisor (2009) - Astellas
Nouira	Yassine	PAUSA1, PAUSA2	Nothing to Disclose
Nouri	Mouad	PL04	Nothing to Disclose
Obara	Kenji	UP-1.58	Nothing to Disclose
Oh	Cheol Young	MP-04.13	Not Received
Oh	Seung-June	MP-05.08, UP-1.05	Nothing to Disclose
Okamura	Takehiko	UP-1.20	Nothing to Disclose
Olapade-Olaopa	E.Oluwabunmi	PAUSA2	Nothing to Disclose
Oliveira	Rui	UP-1.75	Nothing to Disclose
Orsolya Katalin Ilona	Martha	UP-1.19	Not Received
Osaghae	Samuel	MP-05.03, UP-2.42 UP-2.43	Nothing to Disclose
Ouattara	Kalilou	ST01, VVFC	Not Received
Ouegnin	Georges-Armand	PAUSA1	Not Received
Paick	Sung Hyun	UP-2.22	Not Received
Palmas	Artur	MP-06.16	Nothing to Disclose
Papadopoulos	Georgios	MP-05.05, UP-1.45	Nothing to Disclose
Park	Choal Hee	UP-1.15, UP-1.16	Nothing to Disclose



LAST NAME	FIRST NAME	PAPER REF	DISCLOSURE
Park	Heung Jae	MP-06.06	Nothing to Disclose
Park	Jaeshin	MP-06.03, UP-1.22	Nothing to Disclose
Park	Seung Chol	UP-1.21	Nothing to Disclose
Park	Sung-Woo	UP-1.46	Nothing to Disclose
Patris	Emmanuel	UP-1.23, UP-2.59	Nothing to Disclose
Persu	Cristian	MP-06.09, UP-1.59	Nothing to Disclose
Perugia	Giacomo	UP-1.76, UP-1.77	Nothing to Disclose
Petrolekas	Andreas	MP-06.14, UP-2.60	Nothing to Disclose
Pisanti	Francesco	MP-02.17, MP-05.14 UP-2.70	Nothing to Disclose
Pojoga	Oana	UP-1.41	Not Received
Pontari	Michel	PL06	Not Received
Pricop	Catalin	MP-01.03	Not Received
Rabii	Redouane	AMU3, PL04	Nothing to Disclose
Rainauli	Zurab	UP-2.61	Nothing to Disclose
Rao	Pradeep	UP-1.47, VID-1.03	Nothing to Disclose
Ratana-Olarn	Krisada	UP-1.48	Research Fund (2010-2011) - Janssen-Cilag
Retroz	Edson	UP-2.01, UP-2.58	Not Received
Rischmann	Pascal	PAUSA2	Advisor (2007-2010) – GSK; Advisor (2009) – Ferring; Advisor (2010) - Nycomed
Rourke	Keith	MP-02.07, MP-02.08	Advisory Board Member (2010) - GlaxoSmithKline
Ryu	Soo Bang	UP-1.13, UP-1.26	Nothing to Disclose
Sabnis	Ravindra	UP-1.49, UP-1.50	Nothing to Disclose
Sakuyama	Gaku	MP-03.06	Nothing to Disclose
Salazar	Anibal	UP-2.24, UP-2.25	Nothing to Disclose
Samnakay	Saeed	PAUSA1, PAUSA2	Nothing to Disclose
Sarf	Ismail	AMU2, PL05	Not Received
Schaeffer	Anthony	PL03, PL06	Advisor (December 2008) - Alita Pharmaceuticals, Inc.; Advisor (March 2009) - NovaBay Pharmaceuticals, Inc.; Advisor (June 2009) - American Medical Systems; Advisor



LAST NAME	FIRST NAME	PAPER REF	DISCLOSURE
			(August 2009) - Pfizer; Advisor (October 2009) - Propagate Pharma; Advisor (November 2009) - Hagen/Sinclair Research Recruiting, Inc.; Advisor (January 2010) - SPD Development Company
Seki	Narihito	MP-05.04	Nothing to Disclose
Seo	Ju Tae	MP-03.10	Nothing to Disclose
Seo	Youngjun	UP-1.24	Nothing to Disclose
Shaker	Hassan	PL08	Nothing to Disclose
Sharifiaghdas	Farzaneh	UP-1.60, UP-2.05 UP-2.26, UP-2.62	Nothing to Disclose
Sharma	Deen	UP-2.71	Nothing to Disclose
Shin	Dong-Gil	UP-1.25, UP-2.27	Nothing to Disclose
Shirakawa	Toshiro	UP-2.76	Nothing to Disclose
Shishkov	Dimitar	UP-2.46	Nothing to Disclose
Siddiqui	Emad	UP-2.41	Employee (2006-2010) - Astellas Pharma Ltd. UK; Employee (2009-2010, honorary urologist) Ealing Hospital, London
Simforoosh	Nasser	MP-05.06, UP-2.63	Nothing to Disclose
Smit	Shaun	VID-1.07	Nothing to Disclose
Song	Seung-Hun	MP-01.07	Nothing to Disclose
Speakman	Mark	PL05	Not Received
Stanca	Vasile Dan	UP-1.51	Nothing to Disclose
Ströberg	Peter	MP-01.11	Nothing to Disclose
Sul	Chong Koo	MP-03.02, UP-2.28	Nothing to Disclose
Sung	Luck Hee	MP-04.08, MP-04.09	Not Received
Surcel	Cristian	UP-2.29, UP-2.64	Not Received
Tanaka	Tomoaki	MP-03.13	Nothing to Disclose
Thüroff	Joachim	PL05	Nothing to Disclose
Tisdale	Britton E.	MP-02.03	Nothing to Disclose
Tligui	Mohamed	AMU2	Nothing to Disclose
Tokuda	Noriaki	MP-05.07	Nothing to Disclose



LAST NAME	FIRST NAME	PAPER REF	DISCLOSURE
Topuzovic	Cedomir	UP-2.30, UP-2.31	Nothing to Disclose
Touiti	Driss	AMU2	Not Received
Tseng	Yi-Shiou	MP-03.09	Nothing to Disclose
Tu	Le Mai	MP-02.16, UP-2.23	Not Received
Umer	M. Abdul Hamid	UP-2.65	Nothing to Disclose
Valiquette	Luc	PL01	Advisor (Since 2008) - Allergan; Advisor and Speaker (Since 2006) - Astellas; Advisor and Speaker (2006-09) - Janssen-Ortho; Advisor (2007-08) - Oryx; Advisor (Since 2007) - Paladin (Watson); Advisor and Speaker (Since 2001) - Pfizer; Advisor (2007-08) - Purdue; Speaker (2009) - Ranbaxy; Advisor (2007-08) - Triton (Novartis)
Van Der Walt	Chris	MP-01.04, UP-1.52	Nothing to Disclose
Van Kerrebroeck	Philip	MP-01.10, MP-06.04 UP-2.44	Nothing to Disclose
Van Leeuwen	Menno A.	MP-02.01	Nothing to Disclose
Vander Eeckt	Kathy	MP-02.06, UP-2.72 UP-2.73	Nothing to Disclose
Veeramoni	Muthu	UP-1.27, UP-2.74	Nothing to Disclose
Vojinov	Sasa	UP-2.47	Nothing to Disclose
Wadie	Bassem	POD-2.01, VID-1.04 VID-1.05	Invitation (July 21-24, 2010) - Johnson & Johnson
Watya	Stephen	PL04	Nothing to Disclose
Wong	James	MP-02.04	Nothing to Disclose
Wood	Hadley	MP-02.05	Researcher (10/2009 - present) - American Medical Systems
Wu	Wei-Che	UP-1.28	Nothing to Disclose



LAST NAME	FIRST NAME	PAPER REF	DISCLOSURE
Wyndaele	Jean Jacques	PL06, PL08	<p>1. Equity interests (or entitlement to same) of stocks, stock options, royalties, etc, including income from patents or copyrights: None except for Dutch Book of Urology for students published 1998. I wrote one chapter. (&lt; 50 euro /year, exact sum depending on year); 2. Service as a director or employed by a commercial organisation, whether or not remuneration is provided for such service: None; 3. Sole ownership, partnership, or principal of a commercial enterprise: None; 4. Ownership of patent(s): None; 5. Receipt of royalties: None; 6. Consultant to company including positions on medical or scientific advisory boards: Through University and University Hospital (Central accounts); a. Pfizer, Eli Lilly, Novartis, b. One consultancy meeting: Kyowa Hakko, Tanabe Seiyaku, Sumitomo; 7. Honoraria for speaking at company sponsored meeting. Through University and University Hospital (Central accounts) a. Astellas, Pfizer, Novartis, Eli Lilly, Ismar Healthcare; 8. Participation in clinical trials through University Hospital (Central accounts) a. Astellas, Pfizer, GSK, Novartis, Esteril, Allergan, Schwarz, b. Previous 10 years: Jansen-Cilag, Esteve, Yamanouchi, Parexel, Glaxo, PPD, Roche, Fabre, Schering, Pharmacia; 9. Support in the form of fellowships, travel grants, gifts, in-kind donations, Through University Hospital (Central account) a. Astellas, Aventis, Zambon, Glaxo, Innovex, PPD, Synthelabo, Parexel, Bayer, b. For organization local congress oncology: Astra Zeneca, Novartis, Schering, Nycomed, Ipsen, Madaus, Glaxo, Laserscope; 10. Research grants partial or full salary support from a financially commercial organisation for self or employees for whom you are managerially i.e. laboratory technical/research fellow for whom you are managerially responsible.: Procter-Gamble; Pfizer; 11. Any other type of financial or other relationship: Gymna +Enraf Nonius (equipment), University Antwerp (university funding of research).</p>



LAST NAME	FIRST NAME	PAPER REF	DISCLOSURE
Yacoubi	Samira El	AMU3	Not Received
Yalcinkaya	Fatih	UP-1.78	Nothing to Disclose
Yamamoto	Shinya	UP-1.70	Nothing to Disclose
Yang	Stephen S.	MP-05.15	Nothing to Disclose
You	Hyun Wook	POD-2.06	Not Received
Zarrabi	Amir	MP-03.08, MP-05.01	Nothing to Disclose
Zehri	Ali Akbar	MP-02.02	Nothing to Disclose
Zimmermann	Reinhold	MP-03.14, UP-2.32	Nothing to Disclose











